Epidemiology of heart failure with preserved ejection fr

Nature Reviews Cardiology

14, 591-602

DOI: 10.1038/nrcardio.2017.65

Citation Report

#	Article	IF	Citations
1	Limitations of Treating Heart Rate as the Primary Outcome Determinant in OlderÂAdults. Journal of the American College of Cardiology, 2017, 70, 1872-1874.	1.2	0
2	Heart Failure WithÂPreserved EjectionÂFraction. Journal of the American College of Cardiology, 2017, 70, 2458.	1.2	1
3	Pulmonary Hypertension Due to Left Heart Disease. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 662-676.	0.8	1
4	Heart rate in heart failure with preserved ejection fraction: target or marker?. European Journal of Heart Failure, 2017, 19, 1504-1506.	2.9	4
5	Sudden cardiac death and pump failure death prediction in chronic heart failure by combining ECG and clinical markers in an integrated risk model. PLoS ONE, 2017, 12, e0186152.	1.1	38
6	Comorbidities, Sociodemographic Factors, and Hospitalizations in Outpatients With Heart Failure and Preserved Ejection Fraction. American Journal of Cardiology, 2018, 121, 1207-1213.	0.7	14
7	Hormone treatments in congestive heart failure. Journal of International Medical Research, 2018, 46, 2063-2081.	0.4	11
8	Ejection fraction as a statistical index of left ventricular systolic function: the first full allometric scrutiny of its appropriateness and accuracy. Clinical Physiology and Functional Imaging, 2018, 38, 976-985.	0.5	3
10	The Evolving Role of Cardiorespiratory Fitness and Exercise in Prevention and Management of Heart Failure. Current Heart Failure Reports, 2018, 15, 75-80.	1.3	19
11	Sex differences in heart failure. Clinical Cardiology, 2018, 41, 211-216.	0.7	98
12	Taking cardiology clinical trials to the next level: A call to action. Clinical Cardiology, 2018, 41, 179-184.	0.7	22
13	La importancia del estado nutricional en la insuficiencia cardiaca. Revista Clinica Espanola, 2018, 218, 68-69.	0.2	0
14	Mechanisms of physiological and pathological cardiac hypertrophy. Nature Reviews Cardiology, 2018, 15, 387-407.	6.1	925
15	Domain Management Approach to HeartÂFailure in the Geriatric Patient. Journal of the American College of Cardiology, 2018, 71, 1921-1936.	1.2	165
16	Novel heart failure biomarkers: why do we fail to exploit their potential?. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 246-263.	2.7	67
17	The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more?. Heart Failure Reviews, 2018, 23, 631-639.	1.7	26
18	Heart Failure with Preserved Ejection Fraction. Annual Review of Medicine, 2018, 69, 65-79.	5.0	59
19	Sex and Race Differences in Lifetime Risk of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction. Circulation, 2018, 137, 1814-1823.	1.6	124

#	Article	IF	Citations
20	Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. Current Heart Failure Reports, 2018, 15, 10-16.	1.3	6
21	Current themes in myocardial and coronary vascular aging. Current Opinion in Physiology, 2018, 1, 27-33.	0.9	2
22	Physiological proteomics of heart failure. Current Opinion in Physiology, 2018, 1, 185-197.	0.9	1
23	Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment. Trends in Cardiovascular Medicine, 2018, 28, 392-400.	2.3	29
24	Heart failure with preserved ejection fraction: controversies, challenges and future directions. Heart, 2018, 104, 377-384.	1.2	76
25	Participation of Women in Clinical Trials. Journal of the American College of Cardiology, 2018, 71, 1970-1972.	1.2	50
26	Biomarkerâ€based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldoâ€DHF trial. European Journal of Heart Failure, 2018, 20, 1290-1299.	2.9	64
27	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. Circulation: Heart Failure, 2018, 11, e004457.	1.6	31
28	Role of Cardiac Magnetic Resonance in Heart Failure with Preserved Ejection Fraction. Current Cardiovascular Imaging Reports, 2018, 11, 1.	0.4	4
29	Reninâ€“Angiotensinâ€“Aldosterone System Parameters as Biomarker in Heart Failure Patients With Preserved Ejection Fraction: Focus on Angiotensinogen. American Journal of Hypertension, 2018, 31, 175-177.	1.0	3
30	Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies. Journal of Thoracic Disease, 2018, 10, 2034-2045.	0.6	18
31	Physical Activity, Fitness, and Obesity in Heart Failure With Preserved EjectionÂFraction. JACC: Heart Failure, 2018, 6, 975-982.	1.9	111
32	Risk factors for incident heart failure with preserved or reduced ejection fraction, and valvular heart failure, in a community-based cohort. Open Heart, 2018, 5, e000782.	0.9	39
33	The E/eâ€™ ratio difference between subjects with type 2 diabetes and controls. A meta-analysis of clinical studies. PLoS ONE, 2018, 13, e0209794.	1.1	10
34	Heart diseases and echocardiography in rural Tanzania: Occurrence, characteristics, and etiologies of underappreciated cardiac pathologies. PLoS ONE, 2018, 13, e0208931.	1.1	24
35	Mechanisms of Sex Disparities in Cardiovascular Function and Remodeling. , 2018, 9, 375-411.		12
36	Physical Function, Frailty, Cognition, Depression, and Quality of Life in Hospitalized Adults â‰¥60 Years With Acute Decompensated Heart Failure With Preserved Versus Reduced Ejection Fraction. Circulation: Heart Failure, 2018, 11, e005254.	1.6	129
37	Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis. Digestive and Liver Disease, 2018, 50, 1166-1175.	0.4	51

#	Article	IF	Citations
38	The expanding role of implantable devices to monitor heart failure and pulmonary hypertension. Nature Reviews Cardiology, 2018, 15, 770-779.	6.1	22
39	Body Mass Index, Natriuretic Peptides, and Risk of Adverse OutcomesÂin Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial. Journal of the American Heart Association, 2018, 7, e009664.	1.6	16
40	Whatâ€™s new in heart failure therapy 2018?â€. Interactive Cardiovascular and Thoracic Surgery, 2018, 27, 921-930.	0.5	8
41	Obesity Is a Culprit in Heart Failure. JACC: Heart Failure, 2018, 6, 971-972.	1.9	0
42	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology, 2018, 271, 132-139.	0.8	140
43	Obesity and the Obesity Paradox in Heart Failure. Progress in Cardiovascular Diseases, 2018, 61, 151-156.	1.6	205
44	Heart failure with preserved ejection fraction: A systemic disease linked to multiple comorbidities, targeting new therapeutic options. Archives of Cardiovascular Diseases, 2018, 111, 766-781.	0.7	26
45	Histones and heart failure in diabetes. Cellular and Molecular Life Sciences, 2018, 75, 3193-3213.	2.4	23
46	Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H934-H949.	1.5	112
47	Sex-Specific Physiology and Cardiovascular Disease. Advances in Experimental Medicine and Biology, 2018, 1065, 433-454.	0.8	96
48	Sex Differences in Heart Failure. Advances in Experimental Medicine and Biology, 2018, 1065, 529-544.	0.8	43
49	Age-Related Differential Structural and Transcriptomic Responses in the Hypertensive Heart. Frontiers in Physiology, 2018, 9, 817.	1.3	6
50	Primary and Secondary Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2018, 122, 1578-1587.	0.7	37
51	The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: A systematic review and meta-analysis. Diabetes and Vascular Disease Research, 2018, 15, 477-493.	0.9	88
52	Sex Differences in Cardiovascular Pathophysiology. Circulation, 2018, 138, 198-205.	1.6	302
53	Ventricular Arrhythmias Underlie Sudden Death in Rats With Heart Failure and Preserved Ejection Fraction. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006452.	2.1	33
54	Performing sit down medicine in a stand-up place: is it time for palliative care in the emergency department?. Emergency Medicine Journal, 2018, 35, emermed-2018-207967.	0.4	0
55	Systolic and Diastolic Function. , 2018, , 95-103.		0

#	Article	IF	Citations
56	Metabolic remodeling of substrate utilization during heart failure progression. Heart Failure Reviews, 2019, 24, 143-154.	1.7	37
57	Pulmonary vascular disease in the setting of heart failure with preserved ejection fraction. Trends in Cardiovascular Medicine, 2019, 29, 207-217.	2.3	20
58	Personalized Medicine. JACC: Heart Failure, 2019, 7, 732-733.	1.9	2
59	Use of speckle tracking to assess heart failure with preserved ejection fraction. Journal of Cardiology, 2019, 74, 397-402.	0.8	21
60	Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881986159.	1.4	16
61	Divergent Effects of Resveratrol on Rat Cardiac Fibroblasts and Cardiomyocytes. Molecules, 2019, 24, 2604.	1.7	5
62	Estrogen Contributions to Microvascular Dysfunction Evolving to Heart Failure With Preserved Ejection Fraction. Frontiers in Endocrinology, 2019, 10, 442.	1.5	42
63	Effectiveness of the Pharmacist-Involved Multidisciplinary Management of Heart Failure to Improve Hospitalizations and Mortality Rates in 4630 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Cardiac Failure, 2019, 25, 744-756.	0.7	38
64	Aging and human heat dissipation during exercise-heat stress: an update and future directions. Current Opinion in Physiology, 2019, 10, 219-225.	0.9	26
65	Improving risk stratification in heart failure with preserved ejection fraction by combining two validated risk scores. Open Heart, 2019, 6, e000961.	0.9	13
66	Cardiometabolic HeartÂFailure and HFpEF. JACC Basic To Translational Science, 2019, 4, 422-424.	1.9	8
67	The endothelial mineralocorticoid receptor: Contributions to sex differences in cardiovascular disease. , 2019, 203, 107387.		26
68	Biomarkers of Inflammation in Left Ventricular Diastolic Dysfunction. Disease Markers, 2019, 2019, 1-14.	0.6	41
69	Empagliflozin and Protecting Microvascular Support of HeartÂMechanics. JACC Basic To Translational Science, 2019, 4, 592-595.	1.9	1
70	Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Frontiers in Physiology, 2019, 10, 1347.	1.3	81
71	Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. American Journal of Medicine, 2019, 132, S3-S12.	0.6	0
72	Endothelin: 30 Years From Discovery to Therapy. Hypertension, 2019, 74, 1232-1265.	1.3	153
73	Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2019, 6, 143.	1.1	16

#	Article	IF	Citations
74	Marine-Derived Omega-3 Polyunsaturated Fatty Acids and Heart Failure: Current Understanding for Basic to Clinical Relevance. International Journal of Molecular Sciences, 2019, 20, 4025.	1.8	39
75	Noninvasive imaging assessment of rehabilitation therapy in heart failure with preserved and reduced left ventricular ejection fraction (IMAGING-REHAB-HF): design and rationale. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231986837.	1.1	2
76	A mouse model for the most common form of heart failure. Nature, 2019, 568, 324-325.	13.7	9
77	Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and RestoredÂby Empagliflozin. JACC Basic To Translational Science, 2019, 4, 575-591.	1.9	125
78	Different prognostic associations of beta-blockers and diuretics in heart failure with preserved ejection fraction with versus without high blood pressure. Journal of Hypertension, 2019, 37, 643-649.	0.3	7
79	Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction. Trends in Molecular Medicine, 2019, 25, 328-340.	3.5	51
80	Unanswered Questions Regarding Blood Pressure Management for HF Prevention. Current Hypertension Reports, 2019, 21, 7.	1.5	2
81	Association of Undifferentiated Dyspnea in Late Life With Cardiovascular and Noncardiovascular Dysfunction. JAMA Network Open, 2019, 2, e195321.	2.8	20
82	Trabecular cutting: a novel surgical therapy to increase diastolic compliance. Journal of Applied Physiology, 2019, 127, 457-463.	1.2	1
84	Discovery of biomarkers for the presence and progression of left ventricular diastolic dysfunction and HEart faiLure with Preserved ejection Fraction in patients at risk for cardiovascular disease: rationale and design of the HELPFul case-cohort study in a Dutch cardiology outpatient clinic. BMJ Open, 2019, 9, e028408.	0.8	8
85	A hundred heart failure deaths: lessons learnt from the Dr Foster heart failure hospital mortality alert. Open Heart, 2019, 6, e000970.	0.9	4
86	Cardiorenal syndrome in heart failure with preserved ejection fractionâ€”an under-recognized clinical entity. Heart Failure Reviews, 2019, 24, 421-437.	1.7	26
87	Catheter-Based Splanchnic Denervation for Treatment of Hypertensive Cardiomyopathy. Hypertension, 2019, 74, 47-55.	1.3	16
88	The Quality Chasm Between Administrative Coding and Accurate Phenotyping of Heart Failure. Journal of Cardiac Failure, 2019, 25, 490-492.	0.7	2
89	Heart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology. Frontiers in Physiology, 2019, 10, 638.	1.3	87
90	Atrial Functional Mitral Regurgitation. Journal of the American College of Cardiology, 2019, 73, 2465-2476.	1.2	218
91	New mouse model reveals nitrosative stress as a novel driver of HFpEF. Nature Reviews Cardiology, 2019, 16, 383-383.	6.1	5
92	The role of oestrogen in left ventricle (re)modelling in the context of heart failure with preserved ejection fraction. Journal of Physiology, 2019, 597, 2831-2832.	1.3	0

#	Article	IF	Citations
93	Protease-activated receptor 2 deficiency mediates cardiac fibrosis and diastolic dysfunction. European Heart Journal, 2019, 40, 3318-3332.	1.0	39
94	Evaluation of aldosterone antagonist utilization in heart failure with reduced and preserved ejection fraction at an academic medical center. Pharmacy Practice, 2019, 17, 1376.	0.8	1
95	Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. Lancet, The, 2019, 393, 1045-1055.	6.3	48
96	Significant and constant increase in hospitalization due to heart failure in Spain over 15â€¯year period. European Journal of Internal Medicine, 2019, 64, 48-56.	1.0	17
97	Relationships between maintenance of sinus rhythm and clinical outcomes in patients with heart failure with preserved ejection fraction and atrial fibrillation. Journal of Cardiology, 2019, 74, 235-244.	0.8	34
98	Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation, 2019, 139, 1435-1450.	1.6	143
99	Nitrosative stress drives heart failure with preserved ejection fraction. Nature, 2019, 568, 351-356.	13.7	492
100	Think-aloud study about the diagnosis of chronic heart failure in Belgian general practice. BMJ Open, 2019, 9, e025922.	0.8	5
101	Heart Failure with Preserved Ejection Fraction: Time to Revisit the Stiff Heart. Cardiovascular Innovations and Applications, 2019, 3, .	0.1	1
102	Is Cardiac Diastolic Dysfunction a PartÂofÂPost-Menopausal Syndrome?. JACC: Heart Failure, 2019, 7, 192-203.	1.9	46
103	Sex Differences in Heart Failure WithÂPreserved Ejection FractionÂPathophysiology. JACC: Heart Failure, 2019, 7, 239-249.	1.9	82
104	Adverse Drug Reactions to Guideline-Recommended HeartÂFailureÂDrugs in Women. JACC: Heart Failure, 2019, 7, 258-266.	1.9	51
105	Response by Sawaki et al to Letter Regarding Article, â€œVisceral Adipose Tissue Drives Cardiac Aging Through Modulation of Fibroblast Senescence by Osteopontin Productionâ€• Circulation, 2019, 139, 845-846.	1.6	0
106	Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis. Ageing Research Reviews, 2019, 56, 100980.	5.0	107
107	Female Sex Is Protective in a Preclinical Model of Heart Failure With Preserved Ejection Fraction. Circulation, 2019, 140, 1769-1771.	1.6	43
108	Exercise-based cardiac rehabilitation for adults with heart failure. The Cochrane Library, 2019, 2019, CD003331.	1.5	247
109	Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. American Journal of Cardiology, 2019, 124, S3-S11.	0.7	26
110	Heart failure with preserved ejection fraction: present status and future directions. Experimental and Molecular Medicine, 2019, 51, 1-9.	3.2	46

#	Article	IF	Citations
111	Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs. Cells, 2019, 8, 1651.	1.8	39
112	Hypertension, diastolic stress test, and HFpEF: Does new scoring system change something?. Journal of Clinical Hypertension, 2019, 21, 1905-1907.	1.0	3
113	Is PARAGON a Paragon Example of an HFpEF Clinical Trial?. Journal of the American College of Cardiology, 2019, 74, 2874-2877.	1.2	1
114	Stress Echocardiography-Derived E/eâ€™ Predicts Abnormal Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. Frontiers in Physiology, 2019, 10, 1470.	1.3	8
115	HDL-C to hsCRP ratio is associated with left ventricular diastolic function in absence of significant coronary atherosclerosis. Lipids in Health and Disease, 2019, 18, 219.	1.2	3
116	Cardiac hypertrophy with obesity is augmented after pregnancy in C57BL/6 mice. Biology of Sex Differences, 2019, 10, 59.	1.8	6
117	G-Proteinâ€“Coupled Estrogen Receptor Agonist G1 Improves Diastolic Function and Attenuates Cardiac Reninâ€“Angiotensin System Activation in Estrogen-Deficient Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2019, 74, 443-452.	0.8	12
118	Vive les Differences!â€”A case for optimism in the treatment of patients with heart failure and preserved ejection fraction?. International Journal of Clinical Practice, 2019, 73, e13307.	0.8	0
119	CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. Hypertension, 2019, 73, 602-611.	1.3	78
120	Post-systolic shortening: normal values and association with validated echocardiographic and invasive measures of cardiac function. International Journal of Cardiovascular Imaging, 2019, 35, 327-337.	0.7	24
121	The 3A3B score: The simple risk score for heart failure with preserved ejection fraction - A report from the CHART-2 Study. International Journal of Cardiology, 2019, 284, 42-49.	0.8	19
122	Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Failure, 2019, 6, 62-69.	1.4	45
123	Role of autophagy in inherited metabolic and endocrine myopathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 48-55.	1.8	18
124	Diastolic Dysfunction, an Underestimated New Challenge in Dialysis. Therapeutic Apheresis and Dialysis, 2019, 23, 108-117.	0.4	22
125	Molecular Basis of Heart Failure. , 2020, , 1-27.e3.		0
126	Disease Prevention in Heart Failure. , 2020, , 487-500.e4.		0
127	Prior Heart Failure Hospitalization and Outcomes in Patients with Heart Failure with Preserved and Reduced Ejection Fraction. American Journal of Medicine, 2020, 133, 84-94.	0.6	26
128	Sex-Specific Aspects in the Pathophysiology and Imaging of Coronary Macro- and Microvascular Disease. Journal of Cardiovascular Translational Research, 2020, 13, 39-46.	1.1	8

#	Article	IF	Citations
129	Sex and Gender-Related Issues in Heart Failure. Heart Failure Clinics, 2020, 16, 121-130.	1.0	13
130	Mortality after hospital admission for heart failure: improvement over time, equally strong in women as in men. BMC Public Health, 2020, 20, 36.	1.2	26
131	Respiratory support in acute heart failure with preserved vs reduced ejection fraction. Clinical Cardiology, 2020, 43, 320-328.	0.7	5
132	Therapeutic futility and phenotypic heterogeneity in heart failure with preserved ejection fraction: what is the role of bionic learning?. European Journal of Heart Failure, 2020, 22, 159-161.	2.9	4
133	Correlation between longitudinal strain analysis and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Microcirculation, 2020, 27, e12605.	1.0	3
134	Complexity of TNF-Î± Signaling in Heart Disease. Journal of Clinical Medicine, 2020, 9, 3267.	1.0	76
135	Angiotensin Receptor-Neprilysin Inhibitor Therapy for Heart Failure With Preserved Ejection Fraction Improves Renal Outcomes. Circulation, 2020, 142, 1246-1248.	1.6	0
136	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1512.	3.8	170
137	Association of urine albuminâ€toâ€creatinine ratio with subclinical systolic dysfunction in hypertensive patients but not normotensive subjects: Danyang study. Journal of Clinical Hypertension, 2020, 22, 2230-2238.	1.0	2
138	Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1522.	3.8	79
139	Overexpression of endothelial Î²₃â€adrenergic receptor induces diastolic dysfunction in rats. ESC Heart Failure, 2020, 7, 4159-4171.	1.4	10
140	Heart failure with preserved ejection fraction in Belgium: characteristics and outcome of a real-life cohort. Acta Cardiologica, 2021, 76, 697-706.	0.3	6
141	Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. European Journal of Preventive Cardiology, 2021, 28, 975-982.	0.8	35
142	Recurrent hospitalizations are associated with increased mortality across the ejection fraction range in heart failure. ESC Heart Failure, 2020, 7, 2406-2417.	1.4	24
143	Anti-integrin Î±v therapy improves cardiac fibrosis after myocardial infarction by blunting cardiac PW1+ stromal cells. Scientific Reports, 2020, 10, 11404.	1.6	28
144	What Type of Patients Did PARAGON-HF Select? Insights from a Real-World Prospective Cohort of Patients with Heart Failure and Preserved Ejection Fraction. Journal of Clinical Medicine, 2020, 9, 3669.	1.0	7
145	Circulating Vascular Cell Adhesion Moleculeâ€1 and Incident Heart Failure: The Multiâ€Ethnic Study of Atherosclerosis (MESA). Journal of the American Heart Association, 2020, 9, e019390.	1.6	30
146	Contemporary Management of Heart Failure in Patients With Diabetes. Diabetes Care, 2020, 43, 2895-2903.	4.3	20

#	Article	IF	Citations
147	The Global Ambulatory Blood Pressure Monitoring (ABPM) in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry. Rationale, design and objectives. Journal of Human Hypertension, 2020, 35, 1029-1037.	1.0	10
148	Does Weight Loss Improve Clinical Outcomes in Overweight and Obese Patients with Heart Failure?. Current Diabetes Reports, 2020, 20, 75.	1.7	11
149	The Beta3 Adrenergic Receptor in Healthy and Pathological Cardiovascular Tissues. Cells, 2020, 9, 2584.	1.8	43
150	Deficit of resolution receptor magnifies inflammatory leukocyte directed cardiorenal and endothelial dysfunction with signs of cardiomyopathy of obesity. FASEB Journal, 2020, 34, 10560-10573.	0.2	13
151	Sex Hormones and Incident Heart Failure in Men and Postmenopausal Women: The Atherosclerosis Risk in Communities Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3798-e3807.	1.8	39
152	Trends in causeâ€specific readmissions in heart failure with preserved vs. reduced and midâ€range ejection fraction. ESC Heart Failure, 2020, 7, 2894-2903.	1.4	13
153	Addressing Orthostatic Hypotension in Heart Failure: Pathophysiology, Clinical Implications and Perspectives. Journal of Cardiovascular Translational Research, 2020, 13, 549-569.	1.1	9
154	Danshen (Salvia miltiorrhiza) restricts MD2/TLR4â€MyD88 complex formation and signalling in acute myocardial infarctionâ€induced heart failure. Journal of Cellular and Molecular Medicine, 2020, 24, 10677-10692.	1.6	35
155	Statistics of heart failure and mechanical circulatory support in 2020. Annals of Translational Medicine, 2020, 8, 827-827.	0.7	45
156	Value of microalbuminuria in the diagnosis of heart failure with preserved ejection fraction. Herz, 2020, 46, 215-221.	0.4	5
157	Distinct features of calcium handling and Î²â€adrenergic sensitivity in heart failure with preserved versus reduced ejection fraction. Journal of Physiology, 2020, 598, 5091-5108.	1.3	37
158	Plasma trimethylamine n-oxide is associated with renal function in patients with heart failure with preserved ejection fraction. BMC Cardiovascular Disorders, 2020, 20, 394.	0.7	16
159	UMBRELLA protocol: systematic reviews of multivariable biomarker prognostic models developed to predict clinical outcomes in patients with heart failure. Diagnostic and Prognostic Research, 2020, 4, 13.	0.8	4
160	The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. Cardiovascular Research, 2021, 117, 2108-2124.	1.8	108
161	Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?. EMBO Molecular Medicine, 2020, 12, e10865.	3.3	104
162	Left Atrial Strain. JACC: Cardiovascular Imaging, 2020, 13, 2114-2116.	2.3	4
163	Cardiovascular responses to rhythmic handgrip exercise in heart failure with preserved ejection fraction. Journal of Applied Physiology, 2020, 129, 1267-1276.	1.2	17
164	Addressing the sudden cardiac death conundrum in heart failure with preserved ejection fraction: do we need a microscope or a telescope?. European Journal of Heart Failure, 2020, 22, 1930-1932.	2.9	2

#	Article	IF	Citations
165	Sex differences in circulating proteins in heart failure with preserved ejection fraction. Biology of Sex Differences, 2020, 11, 47.	1.8	12
166	Atrial Functional Mitral and Tricuspid Regurgitation. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.4	5
167	Consumption of animal and plant foods and risk of left ventricular diastolic dysfunction: the Bogalusa Heart Study. ESC Heart Failure, 2020, 7, 2700-2710.	1.4	3
168	Change the Laminin, Change the Cardiomyocyte: Improve Untreatable Heart Failure. International Journal of Molecular Sciences, 2020, 21, 6013.	1.8	14
169	Effects of Cardiomyocyte-Specific Deletion of STAT3â€"A Murine Model of Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2020, 7, 613123.	1.1	3
170	Nonâ€severe aortic regurgitation increases shortâ€term mortality in acute heart failure with preserved ejection fraction. ESC Heart Failure, 2020, 7, 3901-3909.	1.4	12
171	Sex Differences in Patients Receiving Left Ventricular Assist Devices for End-Stage HeartÂFailure. JACC: Heart Failure, 2020, 8, 770-779.	1.9	36
172	Mitral Valve Repair of Atrial Functional Mitral Regurgitation in Heart Failure with Preserved Ejection Fraction. Journal of Clinical Medicine, 2020, 9, 3432.	1.0	12
173	Pathophysiological role of fatty acidâ€binding protein 4 in Asian patients with heart failure and preserved ejection fraction. ESC Heart Failure, 2020, 7, 4256-4266.	1.4	21
174	Universality of sex differences in cardiovascular outcomes: where do we go from here?. European Heart Journal, 2020, 41, 1697-1699.	1.0	9
175	Heart failure with preserved ejection fraction: A clustering approach to a heterogenous syndrome. Archives of Cardiovascular Diseases, 2020, 113, 381-390.	0.7	23
176	Both male and female obese ZSF1 rats develop cardiac dysfunction in obesity-induced heart failure with preserved ejection fraction. PLoS ONE, 2020, 15, e0232399.	1.1	26
177	Anabolic Hormones Deficiencies in Heart Failure With Preserved Ejection Fraction: Prevalence and Impact on Antioxidants Levels and Myocardial Dysfunction. Frontiers in Endocrinology, 2020, 11, 281.	1.5	8
178	Epidemiology of heart failure. European Journal of Heart Failure, 2020, 22, 1342-1356.	2.9	948
179	Obesity-Related Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2020, 16, 357-368.	1.0	37
180	Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. Pharmacological Research, 2020, 157, 104781.	3.1	74
181	Basic Mechanisms of Diabetic Heart Disease. Circulation Research, 2020, 126, 1501-1525.	2.0	279
182	Lung Ultrasound for Heart Failure Diagnosis in Primary Care. Journal of Cardiac Failure, 2020, 26, 824-831.	0.7	13

#	Article	IF	Citations
183	Feeding Diastolic Dysfunction: Is It a Bug?. Journal of Cardiac Failure, 2020, 26, 703-704.	0.7	0
184	Subclinical decrease in cardiac autonomic and diastolic function in patients with metabolic disorders: HSCAA study. Metabolism Open, 2020, 5, 100025.	1.4	8
185	Prospective cardiovascular magnetic resonance imaging in adults with AlstrÃ¶m syndrome: silent progression of diffuse interstitial fibrosis. Orphanet Journal of Rare Diseases, 2020, 15, 139.	1.2	3
186	Clinical predictors of allâ€cause mortality in patients presenting to specialist heart failure clinic with raised NTâ€proBNP and no heart failure. ESC Heart Failure, 2020, 7, 1791-1800.	1.4	7
187	Angiotensinâ€“Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2020, 382, 1180-1183.	13.9	21
188	Sex differences in inflammation, redox biology, mitochondria and autoimmunity. Redox Biology, 2020, 31, 101482.	3.9	101
189	Distinctive patterns of inflammation across the heart failure syndrome. Heart Failure Reviews, 2021, 26, 1333-1344.	1.7	32
190	Evaluation and management of heart failure with preserved ejection fraction. Nature Reviews Cardiology, 2020, 17, 559-573.	6.1	339
191	Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. European Journal of Heart Failure, 2020, 22, 1586-1597.	2.9	16
192	Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2020, 7, 2752-2761.	1.4	9
193	The roles of epicardial adipose tissue in heart failure. Heart Failure Reviews, 2022, 27, 369-377.	1.7	20
194	Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model . Clinical Epidemiology, 2020, Volume 12, 607-616.	1.5	15
195	mHealth education interventions in heart failure. The Cochrane Library, 2020, 2020, CD011845.	1.5	34
196	Weight Reduction for Obesity-Induced Heart Failure with Preserved Ejection Fraction. Current Hypertension Reports, 2020, 22, 47.	1.5	14
197	Poor prognosis of heart failure patients with inâ€hospital worsening renal function and elevated BNP at discharge. ESC Heart Failure, 2020, 7, 2912-2921.	1.4	13
198	Heart Failure with Preserved Ejection Fractionâ€”a Concise Review. Current Cardiology Reports, 2020, 22, 82.	1.3	40
199	Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. European Journal of Heart Failure, 2020, 22, 1065-1075.	2.9	31
200	Validating the HFAâ€PEFF score â€“ or how to define a disease?. European Journal of Heart Failure, 2020, 22, 428-431.	2.9	4

#	Article	IF	Citations
201	The Heart Failure with Preserved Ejection Fraction Conundrumâ€"Redefining the Problem and Finding Common Ground?. Current Heart Failure Reports, 2020, 17, 34-42.	1.3	12
202	Mechanisms of atrial fibrillation in aged rats with heart failure with preserved ejection fraction. Heart Rhythm, 2020, 17, 1025-1033.	0.3	34
203	State of the Science in Women's Cardiovascular Disease: A Canadian Perspective on the Influence of Sex and Gender. Journal of the American Heart Association, 2020, 9, e015634.	1.6	114
204	Precision wearable accelerometer contact microphones for longitudinal monitoring of mechano-acoustic cardiopulmonary signals. Npj Digital Medicine, 2020, 3, 19.	5.7	67
205	Immune Dysregulation in HFpEF: A Target for Mesenchymal Stem/Stromal Cell Therapy. Journal of Clinical Medicine, 2020, 9, 241.	1.0	11
206	Quantification of regional myocardial mean intracellular water lifetime: A nonhuman primate study in myocardial stress. NMR in Biomedicine, 2020, 33, e4248.	1.6	3
207	Heart failure after myocardial infarction: Is it all in the risk factors?. REC: CardioClinics, 2020, 55, 1-3.	0.1	0
208	Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2020, 125, 1187-1193.	0.7	26
209	The effect of parity on exercise physiology in women with heart failure with preserved ejection fraction. ESC Heart Failure, 2020, 7, 214-223.	1.4	3
210	Female Heart Health: Is GPER the Missing Link?. Frontiers in Endocrinology, 2019, 10, 919.	1.5	30
211	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. Canadian Journal of Cardiology, 2020, 36, 159-169.	0.8	89
212	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clinical Research in Cardiology, 2020, 109, 1079-1098.	1.5	74
213	Clinical significance of arterial stiffness as a factor for hospitalization of heart failure with preserved left ventricular ejection fraction: a retrospective matched case-control study. Journal of Cardiology, 2020, 76, 171-176.	0.8	10
214	Iron Deficiency: Impact on Functional Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction. Journal of Clinical Medicine, 2020, 9, 1199.	1.0	37
215	Pooled cohort equations heart failure risk score predicts cardiovascular disease and all-cause mortality in a nationally representative sample of US adults. BMC Cardiovascular Disorders, 2020, 20, 202.	0.7	6
216	Impact of the 2016 ASE/EACVI Guidelines on diastolic function reporting in routine clinical practice. Echocardiography, 2020, 37, 546-553.	0.3	2
217	Independence of coronary artery disease to subclinical left ventricular dysfunction. Echocardiography, 2020, 37, 678-687.	0.3	6
218	Effect of Gonadectomy and Angiotensin II Receptor Blockade in a Mouse Model of Isoproterenol-induced Cardiac Diastolic Dysfunction. Journal of Nippon Medical School, 2021, 88, 113-120.	0.3	0

#	Article	IF	Citations
219	Heart Failure With Preserved Ejection Fraction: A Comprehensive Review and Update of Diagnosis, Pathophysiology, Treatment, and Perioperative Implications. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 1839-1859.	0.6	30
220	BMI Is Causally Associated With Pulmonary Artery Pressure But Not Hemodynamic Evidence of Pulmonary Vascular Remodeling. Chest, 2021, 159, 302-310.	0.4	9
221	Metabolic inflammation in heart failure with preserved ejection fraction. Cardiovascular Research, 2021, 117, 423-434.	1.8	102
222	Sex-specific cardiac and vascular responses to hypertension in Chinese populations without overt cardiovascular diseases. Postgraduate Medicine, 2021, 133, 181-187.	0.9	5
223	Targeting Mitochondria-Inflammation Circuit by Î²-Hydroxybutyrate Mitigates HFpEF. Circulation Research, 2021, 128, 232-245.	2.0	190
224	Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life. Journal of Cardiac Failure, 2021, 27, 435-444.	0.7	6
225	Cardiac MRI for the prognostication of heart failure with preserved ejection fraction: A systematic review and meta-analysis. Magnetic Resonance Imaging, 2021, 76, 116-122.	1.0	20
226	ABCs of Heart Failure (HFpEF) Management: Guide for Nurse Practitioners. Journal for Nurse Practitioners, 2021, 17, 168-173.	0.4	0
227	Being in Two Mindsâ€"The Challenge of Heart Failure with Preserved Ejection Fraction Diagnosis with a Single Biomarker. Clinical Chemistry, 2021, 67, 46-49.	1.5	1
228	Mitochondrial Ca2+, redox environment and ROS emission in heart failure: Two sides of the same coin?. Journal of Molecular and Cellular Cardiology, 2021, 151, 113-125.	0.9	24
229	Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches. Postgraduate Medicine, 2021, 133, 125-139.	0.9	8
230	Cardiovascular Autonomic Disturbances in Heart Failure With Preserved Ejection Fraction. Canadian Journal of Cardiology, 2021, 37, 609-620.	0.8	22
231	Heart failure with preserved ejection fraction: disease burden for patients, caregivers, and the health-care system. Postgraduate Medicine, 2021, 133, 140-145.	0.9	8
232	Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial. British Journal of General Practice, 2021, 71, e62-e70.	0.7	13
233	Sex-specific associations of obesity with exercise capacity and diastolic function in Koreans. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 254-262.	1.1	9
234	Complex and Potentially Harmful Medication Patterns in Heart Failure with Preserved Ejection Fraction. American Journal of Medicine, 2021, 134, 374-382.	0.6	14
235	Sweat the small stuff: The human microvasculature and heart disease. Microcirculation, 2021, 28, e12658.	1.0	4
236	French annual national observational study of 2015 outpatient and inpatient healthcare utilization by approximately half a million patients with previous heart failure diagnosis. Archives of Cardiovascular Diseases, 2021, 114, 17-32.	0.7	5

#	Article	IF	Citations
237	Trimetazidine in Heart Failure. Frontiers in Pharmacology, 2020, 11, 569132.	1.6	22
238	Clinical profile and contemporary management of patients with heart failure with preserved ejection fraction: results from the CHECK-HF registry. Netherlands Heart Journal, 2021, 29, 370-376.	0.3	7
239	Subtypes identification on heart failure with preserved ejection fraction via network enhancement fusion using multi-omics data. Computational and Structural Biotechnology Journal, 2021, 19, 1567-1578.	1.9	13
240	Stage D Heart Failure With Preserved Ejection Fraction, Heart Transplantation, and Mechanical Circulatory Support. , 2021, , 276-289.		0
241	Transcatheter Interatrial Shunts for the Treatment of Heart Failure with Preserved Ejection Fraction. International Journal of Cardiovascular Sciences, 2021, 34, 81-88.	0.0	0
242	Risk factors for new-onset heart failure with reduced or preserved ejection fraction in patients with ischemic heart disease: A cohort study. Journal of Clinical Sciences, 2021, 18, 133.	0.0	1
243	Changes in clinical biochemical indexes of patients with heart failure with preserved ejection fraction or patients with hypertensive heart disease before and after treadmill exercise. Annals of Palliative Medicine, 2021, 10, 7970-7976.	0.5	2
244	Efficacy and safety of Xa inhibitors in patients with heart failure and coronary or peripheral artery disease: a systematic review and meta-analysis of randomized controlled trials. Annals of Palliative Medicine, 2021, 10, 8082-8093.	0.5	1
245	Essential Hypertension Worsens Left Ventricular Contractility in Systemic Sclerosis. Journal of Rheumatology, 2021, 48, 1299-1306.	1.0	3
246	Clinical Impact of Worsening Renal Function in Elderly Patients with Acute Decompensated Heart Failure. International Journal of Heart Failure, 2021, 3, 128.	0.9	5
247	Machine learning: at the heart of failure diagnosis. Current Opinion in Cardiology, 2021, 36, 227-233.	0.8	9
248	Impact of primary care involvement and setting on multidisciplinary heart failure management: a systematic review and metaâ€analysis. ESC Heart Failure, 2021, 8, 802-818.	1.4	12
249	Myokines and Heart Failure: Challenging Role in Adverse Cardiac Remodeling, Myopathy, and Clinical Outcomes. Disease Markers, 2021, 2021, 1-17.	0.6	44
250	Cardiologistsâ€™ perceptions on multidisciplinary collaboration in heart failure care - a qualitative study. BMC Health Services Research, 2021, 21, 170.	0.9	8
251	Echocardiographic prognostication of new onset heart failure in a cohort of ischemic heart disease patients. International Journal of Medical and Surgical Sciences, 0, , 1-17.	0.0	0
252	Nicotinamide for the treatment of heart failure with preserved ejection fraction. Science Translational Medicine, 2021, 13, .	5.8	109
253	Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2021, 6, 89-99.	1.9	18
254	A facilitated home-based cardiac rehabilitation intervention for people with heart failure and their caregivers: a research programme including the REACH-HF RCT. Programme Grants for Applied Research, 2021, 9, 1-100.	0.4	8

#	Article	IF	Citations
255	Immuno-metabolic interfaces in cardiac disease and failure. Cardiovascular Research, 2022, 118, 37-52.	1.8	6
257	The Association Between Metformin Treatment and Outcomes in Type 2 Diabetes Mellitus Patients With Heart Failure With Preserved Ejection Fraction: A Retrospective Study. Frontiers in Cardiovascular Medicine, 2021, 8, 648212.	1.1	9
258	Heart failure with preserved ejection fraction: the role of diastolic stress test in diagnostic algorithms. Russian Journal of Cardiology, 2021, 26, 4147.	0.4	2
259	Xbp1s-FoxO1 axis governs lipid accumulation and contractile performance in heart failure with preserved ejection fraction. Nature Communications, 2021, 12, 1684.	5.8	59
260	The use of clinical decision support in reducing readmissions for patients with heart failure: a quasi-experimental study. Contemporary Nurse, 2021, 57, 39-50.	0.4	1
261	Association of fetuin-A levels and left ventricular diastolic dysfunction in patients on haemodialysis. International Urology and Nephrology, 2021, 53, 1689-1694.	0.6	1
262	Cardiac macrophages prevent sudden death during heart stress. Nature Communications, 2021, 12, 1910.	5.8	41
263	Alteration of m6A RNA Methylation in Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 647806.	1.1	33
264	Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction. Annals of Translational Medicine, 2021, 9, 523-523.	0.7	1
265	The Ablation of VEGFR-1 Signaling Promotes Pressure Overload-Induced Cardiac Dysfunction and Sudden Death. Biomolecules, 2021, 11, 452.	1.8	3
266	Cardiac pathophysiology in sickle cell disease. Journal of Thrombosis and Thrombolysis, 2021, 52, 248-259.	1.0	1
267	Prevalence and Prognostic Value of Heart Failure Stages: An Elderly Inpatient Based Cohort Study. Frontiers in Medicine, 2021, 8, 639453.	1.2	3
268	A call to action for new global approaches to cardiovascular disease drug solutions. European Heart Journal, 2021, 42, 1464-1475.	1.0	29
269	Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. Cells, 2021, 10, 881.	1.8	29
270	FABP5 Deficiency Impairs Mitochondrial Function and Aggravates Pathological Cardiac Remodeling and Dysfunction. Cardiovascular Toxicology, 2021, 21, 619-629.	1.1	13
271	A Heterozygous Mutation in Cardiac Troponin T Promotes Ca2+ Dysregulation and Adult Cardiomyopathy in Zebrafish. Journal of Cardiovascular Development and Disease, 2021, 8, 46.	0.8	8
272	Machine learning for subtype definition and risk prediction in heart failure, acute coronary syndromes and atrial fibrillation: systematic review of validity and clinical utility. BMC Medicine, 2021, 19, 85.	2.3	33
273	Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. Clinical Science, 2021, 135, 991-1007.	1.8	18

#	Article	IF	Citations
274	Hydraulic force is a novel mechanism of diastolic function that may contribute to decreased diastolic filling in HFpEF and facilitate filling in HFrEF. Journal of Applied Physiology, 2021, 130, 993-1000.	1.2	2
275	Epidemiologic Characterization of Heart Failure with Reduced or Preserved Ejection Fraction Populations Identified Using Medicare Claims. American Journal of Medicine, 2021, 134, e241-e251.	0.6	14
276	Multimodality assessment of heart failure with preserved ejection fraction skeletal muscle reveals differences in the machinery of energy fuel metabolism. ESC Heart Failure, 2021, 8, 2698-2712.	1.4	16
277	The Relationship between Abnormal Circadian Blood Pressure Rhythm and Risk of Readmission in Patients with Heart Failure with Preserved Ejection Fraction. Cardiovascular Innovations and Applications, 2021, 5, 275-282.	0.1	2
278	Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodiumâ€“glucose co-transporter 2 inhibitors?. Future Cardiology, 2021, 17, 497-506.	0.5	2
279	Alteration of circadian machinery in monocytes underlies chronic kidney disease-associated cardiac inflammation and fibrosis. Nature Communications, 2021, 12, 2783.	5.8	35
280	Hospitalizations for heart failure: still major differences between East and West Germany 30Âyears after reunification. ESC Heart Failure, 2021, 8, 2546-2555.	1.4	11
281	Cardiovascular magnetic resonance predicts all-cause mortality in pulmonary hypertension associated with heart failure with preserved ejection fraction. International Journal of Cardiovascular Imaging, 2021, 37, 3019-3025.	0.7	12
282	Epidemiology of Heart Failure. Circulation Research, 2021, 128, 1421-1434.	2.0	377
283	Zebrafish Heart Failure Models. Frontiers in Cell and Developmental Biology, 2021, 9, 662583.	1.8	35
284	NAD ⁺ Repletion Reverses Heart Failure With Preserved Ejection Fraction. Circulation Research, 2021, 128, 1629-1641.	2.0	96
285	Waist to height ratio is associated with an increased risk of mortality in Chinese patients with heart failure with preserved ejection fraction. BMC Cardiovascular Disorders, 2021, 21, 263.	0.7	9
286	Preclinical rodent models of cardiac fibrosis. British Journal of Pharmacology, 2022, 179, 882-899.	2.7	12
287	Ageâ€related alterations in cardiac and arterial structure and function in hypertensive women and men. Journal of Clinical Hypertension, 2021, 23, 1322-1334.	1.0	11
288	Metabolism and Chronic Inflammation: The Links Between Chronic Heart Failure and Comorbidities. Frontiers in Cardiovascular Medicine, 2021, 8, 650278.	1.1	27
289	S-Nitrosylation of Histone Deacetylase 2 by Neuronal Nitric Oxide Synthase as a Mechanism of Diastolic Dysfunction. Circulation, 2021, 143, 1912-1925.	1.6	28
290	A peptide of the amino-terminus of GRK2 induces hypertrophy and yet elicits cardioprotection after pressure overload. Journal of Molecular and Cellular Cardiology, 2021, 154, 137-153.	0.9	9
291	Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2021, 146, 36-47.	0.7	15

#	Article	IF	Citations
292	Association of Major Depressive Disorder on Heart Failure With Reduced and Preserved Ejection Fraction: Analysis of National Readmission Database 2018. Cureus, 2021, 13, e15107.	0.2	0
293	Sex-Specific Differences of the Inflammatory State in Experimental Autoimmune Myocarditis. Frontiers in Immunology, 2021, 12, 686384.	2.2	22
294	Falla cardiaca con fracciÃ³n de eyecciÃ³n preservada: generalidades y aproximaciÃ³n en el perioperatorio. Revista Med, 2021, 28, 49-60.	0.1	0
295	A Review of the Role of Type 2 Diabetes and SGLT2 Inhibitors in Heart Failure with Preserved Ejection Fraction. Cardiology in Review, 2021, Publish Ahead of Print, .	0.6	1
296	Obesity-associated cardiovascular risk in women: hypertension and heart failure. Clinical Science, 2021, 135, 1523-1544.	1.8	20
297	Heart Failure Primary Prevention: What Does SPRINT Add?: Recent Advances in Hypertension. Hypertension, 2021, 77, 1804-1814.	1.3	5
298	Emergency physician bedside echocardiographic identification of left ventricular diastolic dysfunction. American Journal of Emergency Medicine, 2021, 44, 20-25.	0.7	1
299	The Goto Kakizaki rat: Impact of age upon changes in cardiac and renal structure, function. PLoS ONE, 2021, 16, e0252711.	1.1	5
300	High Neutrophil to Lymphocyte Ratio and Its Gene Signatures Correlate With Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 614757.	1.1	19
301	The Role of HECT-Type E3 Ligase in the Development of Cardiac Disease. International Journal of Molecular Sciences, 2021, 22, 6065.	1.8	11
302	Heart failure with preserved ejection fraction based on aging and comorbidities. Journal of Translational Medicine, 2021, 19, 291.	1.8	14
303	Heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus: pathophysiology and treatment options. Medical Herald of the South of Russia, 2021, 12, 6-15.	0.2	1
304	A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. Circulation, 2021, 144, 159-169.	1.6	18
305	Chronic Sildenafil Therapy in the ZSF1 Obese Rat Model of Metabolic Syndrome and Heart Failure With Preserved Ejection Fraction. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 690-701.	1.0	9
306	Hypertension and Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2021, 17, 337-343.	1.0	6
307	Myocardial Tissue Characterization in Heart Failure with Preserved Ejection Fraction: From Histopathology and Cardiac Magnetic Resonance Findings to Therapeutic Targets. International Journal of Molecular Sciences, 2021, 22, 7650.	1.8	17
308	Delayed repolarization and ventricular tachycardia in patients with heart failure and preserved ejection fraction. PLoS ONE, 2021, 16, e0254641.	1.1	8
309	Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life. Journal of Cardiac Failure, 2021, 27, 1382-1392.	0.7	3

#	Article	IF	Citations
310	Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes. Progress in Cardiovascular Diseases, 2021, 67, 89-97.	1.6	12
311	Aldosterone dysregulation predicts the risk of mortality and rehospitalization in heart failure with a preserved ejection fraction. Science China Life Sciences, 2021, , 1.	2.3	5
312	Current Prevalence, Incidence, and Outcomes of Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2021, 17, 315-326.	1.0	18
313	Heart failure medication dosage and survival in women and men seen at outpatient clinics. Heart, 2021, 107, 1748-1755.	1.2	20
314	Heart Failure with Preserved Ejection Fraction: Current Opinion and Future Perspectives. Heart Failure Clinics, 2021, 17, xiii-xiv.	1.0	3
315	Unveiling the role of exercise training in targeting the inflammatory paradigm of heart failure with preserved ejection fraction: a narrative review. Heart Failure Reviews, 2021, , 1.	1.7	3
316	EpidemiologÃa de la insuficiencia cardiaca con fracciÃ³n de eyecciÃ³n preservada: resultados del Registro RICA. Medicina ClÃnica, 2021, 157, 1-9.	0.3	15
317	Epidemiology of heart failure with preserved ejection fraction: Results from the RICA Registry. Medicina ClÃnica (English Edition), 2021, 157, 1-9.	0.1	1
318	Predicting incident heart failure in women with machine learning: The Women's Health Initiative Cohort. Canadian Journal of Cardiology, 2021, 37, 1708-1714.	0.8	8
319	Multiple roles of cardiac macrophages in heart homeostasis and failure. Heart Failure Reviews, 2022, 27, 1413-1430.	1.7	24
320	Association Between Arterial Stiffness and Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 707162.	1.1	9
321	Heart Failure Syndrome With Preserved Ejection Fraction Is a Metabolic Cluster of Non-resolving Inflammation in Obesity. Frontiers in Cardiovascular Medicine, 2021, 8, 695952.	1.1	13
322	Prognosticators of All-Cause Mortality in Patients With Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2021, 158, 66-73.	0.7	6
323	Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 926.	3.0	65
324	A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 3495-3503.	1.4	3
325	Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models. European Heart Journal, 2021, 42, 4420-4430.	1.0	65
326	Temporal trends in the burden of heart failure. Internal Medicine Journal, 2021, 51, 1212-1218.	0.5	14
327	Metabolic Syndrome Mediates ROS-miR-193b-NFYAâ€“Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. Circulation, 2021, 144, 615-637.	1.6	44

#	Article	IF	Citations
328	Applying the ESC 2016, H₂FPEF, and HFAâ€PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the general population. ESC Heart Failure, 2021, 8, 3603-3612.	1.4	23
329	Chronic lowâ€grade inflammation in heart failure with preserved ejection fraction. Aging Cell, 2021, 20, e13453.	3.0	33
330	Pharmacological Tuning of Adenosine Signal Nuances Underlying Heart Failure With Preserved Ejection Fraction. Frontiers in Pharmacology, 2021, 12, 724320.	1.6	2
331	Diagnostic Performance of Serum Biomarkers Fibroblast Growth Factor 21, Galectin-3 and Copeptin for Heart Failure with Preserved Ejection Fraction in a Sample of Patients with Type 2 Diabetes Mellitus. Diagnostics, 2021, 11, 1577.	1.3	9
332	The effects of sacubitril/valsartan on heart failure with preserved ejection fraction: a meta-analysis. Acta Cardiologica, 2022, 77, 471-479.	0.3	3
333	Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair. JACC: Cardiovascular Interventions, 2021, 14, 2010-2021.	1.1	27
334	Association Between Metabolic Syndrome and an Increased Risk of Hospitalization for Heart Failure in Population of HFpEF. Frontiers in Cardiovascular Medicine, 2021, 8, 698117.	1.1	7
335	Echocardiographic Assessments for Peripartum Cardiac Events in Pregnant Women with Low-Risk Congenital Heart Disease. International Heart Journal, 2021, 62, 1062-1068.	0.5	3
336	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1577-1596.	2.9	23
337	Ubiquitin ligase Wwp1 gene deletion attenuates diastolic dysfunction in pressure-overload hypertrophy. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H976-H984.	1.5	5
338	Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population. Drugs - Real World Outcomes, 2022, 9, 53-62.	0.7	5
339	Rhythm Control in Patients with Heart Failure with Preserved Ejection Fraction: A Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 4038.	1.0	4
340	Phenotyping heart failure using modelâ€based analysis and physiologyâ€informed machine learning. Journal of Physiology, 2021, 599, 4991-5013.	1.3	16
341	Sex Differences and Regulatory Actions of Estrogen in Cardiovascular System. Frontiers in Physiology, 2021, 12, 738218.	1.3	26
342	Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review. Journal of Clinical Medicine, 2021, 10, 4497.	1.0	10
343	Risk prediction model of in-hospital mortality in heart failure with preserved ejection fraction and mid-range ejection fraction: a retrospective cohort study. Biomarkers in Medicine, 2021, 15, 1223-1232.	0.6	1
345	Mitochondrial function, dynamics and quality control in the pathophysiology of HFpEF. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166208.	1.8	17
346	Reliable prognostic markers for the progression of heart failure in older adults: Is ambulatory blood pressure monitoring one of them?. Revista Clínica Espanõla, 2021, 221, 470-472.	0.3	0

#	Article	IF	Citations
347	The role of systolicâ€“diastolic coupling in distinguishing impaired diastolic recoil in healthy aging and heart failure with preserved ejection fraction. Echocardiography, 2021, 38, 261-270.	0.3	4
348	Cardiometabolic HFpEF: Mechanisms and Therapies. Cardiometabolic Syndrome Journal, 2021, 1, 117.	1.0	1
349	Domain management as the best way of manage patient with heart failure and geriatrics syndromes. Russian Journal of Geriatric Medicine, 2021, , 313-326.	0.3	1
350	Patients characteristics and prognostic implications of type 2 diabetes mellitus in heart failure with preserved, mid-rang reduced and reduced ejection fraction. Medicinski Podmladak, 2021, 72, 18-24.	0.2	0
351	Sex differences in the incidence and mode of death in rats with heart failure with preserved ejection fraction. Experimental Physiology, 2021, 106, 673-682.	0.9	7
352	Clinical Phenotypes and Age-Related Differences in Presentation, Treatment, and Outcome of Heart Failure with Preserved Ejection Fraction: A Vietnamese Multicenter Research. Cardiology Research and Practice, 2021, 2021, 1-9.	0.5	5
353	Bayesian Feature Pyramid Networks for Automatic Multi-label Segmentation of Chest X-rays and Assessment of Cardio-Thoratic Ratio. Lecture Notes in Computer Science, 2020, , 117-130.	1.0	10
354	Consensus document: management of heart failure in type 2 diabetes mellitus. Heart Failure Reviews, 2021, 26, 1037-1062.	1.7	3
355	Atrial functional versus ventricular functional mitral regurgitation: Prognostic implications. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1808-1815.e4.	0.4	11
357	Enhancing diastolic function by strain-dependent detachment of cardiac myosin crossbridges. Journal of General Physiology, 2020, 152, .	0.9	7
359	Exercise training reverses cardiac aging phenotypes associated with heart failure with preserved ejection fraction in male mice. Aging Cell, 2020, 19, e13159.	3.0	46
360	A randomised controlled trial of a facilitated home-based rehabilitation intervention in patients with heart failure with preserved ejection fraction and their caregivers: the REACH-HFpEF Pilot Study. BMJ Open, 2018, 8, e019649.	0.8	66
361	Cohort profile: FACE, prospective follow-up of chronic heart failure patients with sleep-disordered breathing indicated for adaptive servo ventilation. BMJ Open, 2020, 10, e038403.	0.8	10
362	Novel Findings From a Metabolomics Study of Left Ventricular Diastolic Function: The Bogalusa Heart Study. Journal of the American Heart Association, 2020, 9, e015118.	1.6	25
363	Reverse electrical remodeling in rats with heart failure and preserved ejection fraction. JCI Insight, 2018, 3, .	2.3	22
364	Non-invasive Low-level Tragus Stimulation in Cardiovascular Diseases. Arrhythmia and Electrophysiology Review, 2020, 9, 40-46.	1.3	26
365	2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, 25, 4083.	0.4	229
366	2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, 25, 4083.	0.4	32

#	Article	IF	Citations
368	Management of heart failure with preserved ejection fraction. Australian Prescriber, 2020, 43, 12-17.	0.5	6
369	Gender particulars of morphological phenotypes of the right atrial appendage myocardium in patients with chronic heart failure who underwent an open heart surgery. AlÊ¹manah KliniÄeskoj Mediciny, 2018, 46, 355-366.	0.2	2
370	Palliative Care and Advance Care Planning in Pulmonary Hypertension. Advances in Pulmonary Hypertension, 2018, 17, 15-19.	0.1	6
371	Hemodynamic Instability in Heart Failure Intensifies Age-Dependent Cognitive Decline. Journal of Alzheimer's Disease, 2020, 76, 63-84.	1.2	6
372	The Molecular and Cellular Mechanisms Associated with a Microvascular Inflammation in the Pathogenesis of Heart Failure with Preserved Ejection Fraction. Acta Naturae, 2020, 12, 40-51.	1.7	10
373	A Sex-Specific Role of Endothelial Sirtuin 3 on Blood Pressure and Diastolic Dysfunction in Female Mice. International Journal of Molecular Sciences, 2020, 21, 9744.	1.8	11
374	Sex and Gender Differences in Heart Failure. International Journal of Heart Failure, 2020, 2, 157.	0.9	43
375	EquilÃbrio DinÃ¢mico e Mobilidade Explicam a Qualidade de Vida na ICFEP, Superando Todos os Outros Componentes da AptidÃ£o FÃsica. Arquivos Brasileiros De Cardiologia, 2020, 114, 701-707.	0.3	8
376	Using Sensor Signals in the Early Detection of Heart Failure: A Case Study. Journal of Gerontological Nursing, 2020, 46, 41-46.	0.3	13
377	CRP Induces NETosis in Heart Failure Patients with or without Diabetes. ImmunoHorizons, 2019, 3, 378-388.	0.8	28
378	Heart Failure with Preserved Ejection Fraction: the Major Unmet Need in Cardiology. Korean Circulation Journal, 2020, 50, 1051.	0.7	15
379	Range of adiposity and cardiorenal syndrome. World Journal of Diabetes, 2020, 11, 322-350.	1.3	13
380	Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction. World Journal of Cardiology, 2020, 12, 7-25.	0.5	28
381	Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers. World Journal of Cardiology, 2020, 12, 373-408.	0.5	61
382	On the search for the right definition of heart failure with preserved ejection fraction. Cardiology Journal, 2020, 27, 449-468.	0.5	13
384	A Multivariate Model to Predict Chronic Heart Failure after Acute ST-Segment Elevation Myocardial Infarction: Preliminary Study. Diagnostics, 2021, 11, 1925.	1.3	2
385	Sex Differences in Characteristics and Outcomes in Elderly Heart Failure Patients With Preserved Ejection Fraction: A Post-hoc Analysis From TOPCAT. Frontiers in Cardiovascular Medicine, 2021, 8, 721850.	1.1	3
386	Prognostic impact of systolic blood pressure in acute heart failure with preserved ejection fraction in older patients. ESC Heart Failure, 2021, 8, 5493-5500.	1.4	3

#	Article	IF	Citations
387	Lipotoxicity: a driver of heart failure with preserved ejection fraction?. Clinical Science, 2021, 135, 2265-2283.	1.8	22
388	RyR2 and Calcium Release in Heart Failure. Frontiers in Physiology, 2021, 12, 734210.	1.3	31
389	Modification effect of ideal cardiovascular health metrics on genetic association with incident heart failure in the China Kadoorie Biobank and the UK Biobank. BMC Medicine, 2021, 19, 259.	2.3	4
390	Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial. Cells, 2021, 10, 2796.	1.8	3
391	Recognition, Diagnosis, and Management of Heart Failure with Preserved Ejection Fraction. US Cardiology Review, 2018, 12, 8-12.	0.5	0
392	The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition. Drugs in Context, 2018, 7, 1-11.	1.0	0
393	Geographical Variations in Patients with Heart Failure and Preserved Ejection Fraction: A Sub-Group Analysis of the APOLLON Registry. Balkan Medical Journal, 2019, 36, 235-244.	0.3	1
395	Prognostic Significance of Diastolic Dysfunction With Multiple Comorbidities in Heart Failure Patients. Cureus, 2020, 12, e8297.	0.2	2
397	Comparison of Perioperative Outcomes in Heart Failure Patients With Reduced Versus Preserved Ejection Fraction After Noncardiac Surgery. Annals of Surgery, 2022, 275, 807-815.	2.1	7
398	Dynamics of Vascular Stiffness and Endothelial Function in Combination Therapy of Heart Failure with Preserved Ejection Fraction. Rational Pharmacotherapy in Cardiology, 2020, 16, 377-382.	0.3	0
400	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). Eurasian Heart Journal, 2020, , 6-76.	0.2	6
401	The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine, 2021, 27, 1954-1960.	15.2	299
402	Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study. Revista Espanola De Cardiologia (English Ed), 2022, 75, 31-38.	0.4	20
403	Do patients with heart failure and preserved, mid-range or reduced ejection fraction have different outcomes?. Cor Et Vasa, 2020, 62, 567-573.	0.1	1
404	Skeletal muscle (dys)function in heart failure with preserved ejection fraction. Current Opinion in Cardiology, 2021, 36, 219-226.	0.8	2
405	Major depression and clinical outcomes in patients with heart failure with preserved ejection fraction. European Journal of Clinical Investigation, 2021, 51, e13401.	1.7	6
407	Novel technologies in the management of heart failure with preserved ejection fraction: a promise during the time of disappointment from pharmacological approaches?. Current Opinion in Cardiology, 2021, 36, 211-218.	0.8	0
408	The Role of Neprilysin Inhibitors in the Treatment of Heart Failure with Preserved Ejection Fraction. Kardiologiya, 2020, 60, 117-127.	0.3	3

#	Article	IF	Citations
409	Management of Heart Failure in Older Adults with Dementia. , 2020, , 53-76.		0
410	Cardioprotective responses to aerobic exercise-induced physiological hypertrophy in zebrafish heart. Journal of Physiological Sciences, 2021, 71, 33.	0.9	9
414	Heart failure with preserved ejection fraction in the elderly: pathophysiology, diagnostic and therapeutic approach. Journal of Geriatric Cardiology, 2019, 16, 421-428.	0.2	10
415	Chronic Heart Failure with Normal Contractility. MÃ¦dica, 2019, 14, 79-80.	0.4	0
416	Prognostic value of serum hyponatremia for outcomes in patients with heart failure with preserved ejection fraction: An observational cohort study. Experimental and Therapeutic Medicine, 2020, 20, 101.	0.8	1
417	Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fraction-A Specific HFpEF Phenotype. Frontiers in Cardiovascular Medicine, 2021, 8, 720690.	1.1	3
419	Iron Deficiency in Heart Failure: Characteristics and Treatment. Current Geriatrics Reports, 2021, 10, 196-205.	1.1	5
420	Echocardiography in the diagnostic evaluation and phenotyping of heart failure with preserved ejection fraction. Journal of Cardiology, 2022, 79, 679-690.	0.8	8
421	Sexual dimorphism in cardiac remodeling: the molecular mechanisms ruled by sex hormones in the heart. Journal of Molecular Medicine, 2022, 100, 245-267.	1.7	4
422	MicroRNA-Related Strategies to Improve Cardiac Function in Heart Failure. Frontiers in Cardiovascular Medicine, 2021, 8, 773083.	1.1	13
423	Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. Drugs in R and D, 2022, 22, 25-33.	1.1	11
424	Aetiological classification and prognosis in patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2022, 9, 519-530.	1.4	16
425	Skeletal myopathy in a rat model of postmenopausal heart failure with preserved ejection fraction. Journal of Applied Physiology, 2022, 132, 106-125.	1.2	4
426	SGLT2 inhibitors: further evidence for heart failure with preserved ejection fraction as a metabolic disease?. Journal of Clinical Investigation, 2021, 131, .	3.9	4
427	The Prognostic Value of Lung Ultrasound in Patients With Newly Diagnosed Heart Failure With Preserved Ejection Fraction in the Ambulatory Setting. Frontiers in Cardiovascular Medicine, 2021, 8, 758147.	1.1	4
428	Relation of intestinal microbiota composition to extracellular matrix volume assessed by myocardial T1 mapping in patients with chronic heart failure and preserved left ventricular ejection fraction. Profilakticheskaya Meditsina, 2021, 24, 28.	0.2	1
429	Mitochondrial protein hyperacetylation underpins heart failure with preserved ejection fraction in mice. Journal of Molecular and Cellular Cardiology, 2022, 165, 76-85.	0.9	29
430	Prognostic value of serum hyponatremia for outcomes in patients with heart failure with preserved ejection fraction: An observational cohort study. Experimental and Therapeutic Medicine, 2020, 20, 1-1.	0.8	5

#	Article	IF	Citations
431	Bariatric Surgery as a Bridge to Heart Transplantation in Morbidly Obese Patients. Cardiology in Review, 2022, 30, 1-7.	0.6	8
432	Chronische Herzinsuffizienz: Selten isoliert, daher fordernd. , 0, , .		0
433	Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fractionâ€"A Specific HFpEF Phenotype. Frontiers in Cardiovascular Medicine, 2021, 8, 720690.	1.1	25
434	Deciphering the Protein, Modular Connections and Precision Medicine for Heart Failure With Preserved Ejection Fraction and Hypertension Based on TMT Quantitative Proteomics and Molecular Docking. Frontiers in Physiology, 2021, 12, 607089.	1.3	4
435	Biomarker-Based Guideline-Directed Medical Therapy of Heart Failure: The Gap Between Guidelines and Clinical Practice. EMJ Cardiology, 0, , 67-76.	0.0	0
436	The roles of global longitudinal strain imaging in contemporary clinical cardiology. Journal of Medical Ultrasonics (2001), 2022, 49, 175-185.	0.6	5
437	Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart, 2022, 108, 1342-1350.	1.2	81
438	Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy. BMC Medicine, 2022, 20, 21.	2.3	5
439	A deep learning model for early risk prediction of heart failure with preserved ejection fraction by DNA methylation profiles combined with clinical features. Clinical Epigenetics, 2022, 14, 11.	1.8	12
440	Impact of Left Ventricular Chamber Size on Outcome in Heart Failure with Preserved Ejection Fraction. International Heart Journal, 2022, 63, 62-72.	0.5	3
441	Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors. Diabetes Therapy, 2022, 13, 241-250.	1.2	11
443	A Preclinical Rat Model of Heart Failure With Preserved Ejection Fraction With Multiple Comorbidities. Frontiers in Cardiovascular Medicine, 2021, 8, 809885.	1.1	6
444	Transcatheter Implantation of Interatrial Shunt Devices to Lower Left Atrial Pressure in Heart Failure. International Journal of Heart Failure, 2022, 4, 12.	0.9	2
445	Focus on HFpEF in heart failure. Chinese Medical Journal, 2022, 135, 1041-1042.	0.9	1
446	Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes. Current Atherosclerosis Reports, 2022, 24, 109-117.	2.0	4
447	Hospitalization following an emergency-department visit for worsening heart failure: The role of left ventricular ejection fraction. Medicina ClÃnica, 2022, 159, 157-163.	0.3	1
448	Associations between calcium channel blocker therapy and mortality in heart failure with preserved ejection fraction. European Journal of Preventive Cardiology, 2022, 29, 1343-1351.	0.8	5
449	Trends in the amyloidosis mortality rate in J apan: A nationwide observational study from 1998 to 2019. Geriatrics and Gerontology International, 2022, , .	0.7	1

#	Article	IF	Citations
450	Diagnostic Value of Serum Concentration of Galectin-3 in Patients With Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 829151.	1.1	4
451	Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): systematic review and meta-analysis. Heart Failure Reviews, 2022, 27, 1933-1955.	1.7	12
452	Representation of women in heart failure clinical trials: Barriers to enrollment and strategies to close the gap. American Heart Journal Plus, 2022, 13, 100093.	0.3	13
454	Inferior Vena Cava Edge Tracking Echocardiography: A Promising Tool with Applications in Multiple Clinical Settings. Diagnostics, 2022, 12, 427.	1.3	5
455	Exercise Systolic Reserve and Exercise Pulmonary Hypertension Improve Diagnosis of Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2022, 9, 814601.	1.1	1
457	Sudden Death and Ventricular Arrhythmias in Heart Failure With Preserved Ejection Fraction. Korean Circulation Journal, 2022, 52, 251.	0.7	7
458	Qualitative and Quantitative Effects of Fatty Acids Involved in Heart Diseases. Metabolites, 2022, 12, 210.	1.3	6
459	Role of Distinct Macrophage Populations in the Development of Heart Failure in Macrophage Activation Syndrome. International Journal of Molecular Sciences, 2022, 23, 2433.	1.8	3
460	Predictors and Mortality for Worsening Left Ventricular Ejection Fraction in Patients With HFpEF. Frontiers in Cardiovascular Medicine, 2022, 9, 820178.	1.1	3
461	Sex Differences in Cardiac Rehabilitation Outcomes. Circulation Research, 2022, 130, 552-565.	2.0	26
462	The Prognostic Value of Anemia in Patients with Preserved, Mildly Reduced and Recovered Ejection Fraction. Diagnostics, 2022, 12, 517.	1.3	7
463	Age and Sex Differences in Heart Failure With Preserved Ejection Fraction. Frontiers in Aging, 2022, 3, .	1.2	4
464	Influences of achieved SBP on age and sex-related left ventricular structural alteration in community hypertensive populations. Journal of Hypertension, 2022, Publish Ahead of Print, .	0.3	7
465	Comparison of classifications and justification of the need for transdisciplinary consensus to take into account the prevalence and mortality associated with chronic heart failure. Complex Issues of Cardiovascular Diseases, 2022, 11, 6-16.	0.3	2
466	Ellagic acid prevents myocardial infarction-induced left ventricular diastolic dysfunction in ovariectomized rats. Journal of Nutritional Biochemistry, 2022, 105, 108990.	1.9	4
467	Immunometabolic mechanisms of heart failure with preserved ejection fraction. , 2022, 1, 211-222.		27
468	Epigenetic remodeling in heart failure with preserved ejection fraction. Current Opinion in Cardiology, 2022, 37, 219-226.	0.8	7
469	Mitral valve edgeâ€toâ€edge repair versus indirect mitral valve annuloplasty in atrial functional mitral regurgitation. Catheterization and Cardiovascular Interventions, 2022, 99, 1839-1847.	0.7	6

#	Article	IF	Citations
470	Sodiumâ€glucose cotransporterâ€2 inhibitors in heart failure: an updated metaâ€analysis. ESC Heart Failure, 2022, 9, 1942-1953.	1.4	9
471	The HFAâ€PEFF score identifies â€˜earlyâ€HFpEFâ€™ phenogroups associated with distinct biomarker profiles. ESC Heart Failure, 2022, 9, 2032-2036.	1.4	6
473	An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats. Frontiers in Pharmacology, 2022, 13, 856386.	1.6	9
474	Exercise Stress Echocardiography in the Diagnostic Evaluation of Heart Failure with Preserved Ejection Fraction. Journal of Cardiovascular Development and Disease, 2022, 9, 87.	0.8	5
475	Comparison of device-based therapy options for heart failure with preserved ejection fraction: a simulation study. Scientific Reports, 2022, 12, 5761.	1.6	6
476	Prevalence and clinical characteristics of sleep-disordered breathing in patients with heart failure of different left ventricular ejection fractions. Sleep and Breathing, 2023, 27, 245-253.	0.9	8
477	Identification of DNA Damage Repair Enzyme Ascc2 as Causal for Heart Failure With Preserved Ejection Fraction. Circulation, 2022, 145, 1102-1104.	1.6	6
478	Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 869272.	1.1	6
479	Female Gender Is Associated with an Increased Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure with Reduced Ejection Fraction. Medical Sciences (Basel, Switzerland), 2022, 10, 21.	1.3	5
480	Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from <scp>HOMAGE</scp> and the <scp>UK</scp> Biobank. European Journal of Heart Failure, 2022, 24, 976-984.	2.9	5
481	Comparing Machine Learning Models and Statistical Models for Predicting Heart Failure Events: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 812276.	1.1	11
482	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001063.	1.6	756
483	Defining changes in physical limitation from the patient perspective: insights from the <scp>VITALITYâ€HFpEF</scp> randomized trial. European Journal of Heart Failure, 2022, , .	2.9	8
484	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2022, 79, e263-e421.	1.2	774
485	Heart failure with preserved ejection fraction: An age-related condition. Journal of Molecular and Cellular Cardiology, 2022, 167, 83-84.	0.9	4
486	Aortic root systolic excursion and its association with exercise tolerance in patients with heart failure with preserved ejection fraction. Journal of Cardiology & Current Research, 2021, 14, 155-161.	0.1	1
487	A Stepwise Guide to the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 1016-1030.	0.7	5
488	Under-Enrollment of Obese Heart Failure with Preserved Ejection Fraction Patients in Major HFpEF Clinical Trials. Journal of Cardiac Failure, 2022, 28, 723-731.	0.7	3

#	Article	IF	Citations
489	Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction. ESC Heart Failure, 2022, 9, 133-145.	1.4	22
490	The role of FGF21 in the pathogenesis of cardiovascular disease. Chinese Medical Journal, 2021, 134, 2931-2943.	0.9	25
491	Heart failure with preserved, midâ€range, and reduced ejection fraction across health care settings: an observational study. ESC Heart Failure, 2022, 9, 363-372.	1.4	17
492	Sex-Based Differences in HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 1530-1541.	1.2	22
493	Cardiac remodeling in ambitious endurance-trained amateur athletes older than 50 yearsâ€“an observational study. PLoS ONE, 2022, 17, e0266951.	1.1	1
495	Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer. Breast Cancer Research and Treatment, 2022, 193, 669-675.	1.1	4
496	Abdominal Obesity Is Associated with an Increased Risk of All-Cause Mortality in Males but Not in Females with HFpEF. Cardiovascular Therapeutics, 2022, 2022, 1-11.	1.1	2
497	Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 854501.	1.1	9
498	Metabolic therapy for managing heart failure with preserved ejection fraction. Journal of Molecular and Cellular Cardiology, 2022, 168, 68-69.	0.9	2
499	Sex and Gender-Related Issues in Heart Failure. Cardiology Clinics, 2022, 40, 259-268.	0.9	3
500	Cardiovascular disease and the biology of aging. Journal of Molecular and Cellular Cardiology, 2022, 167, 109-117.	0.9	11
507	Signaling cascades in the failing heart and emerging therapeutic strategies. Signal Transduction and Targeted Therapy, 2022, 7, 134.	7.1	18
510	Left Atrial Ejection Force as a Marker for the Diagnosis of Heart Failure with Preserved Ejection Fraction.. Journal of Cardiovascular Echography, 2021, 31, 125-130.	0.1	0
511	LCZ696 Ameliorates Isoproterenol-Induced Acute Heart Failure in Rats by Activating the Nrf2 Signaling Pathway. Applied Bionics and Biomechanics, 2022, 2022, 1-9.	0.5	6
512	Physical Exercise Modalities for the Management of Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Pharmacology, 2022, 79, 698-710.	0.8	5
513	The Association of Nutritional Risk Screening 2002 With 1-Year Re-hospitalization and the Length of Initial Hospital Stay in Patients With Heart Failure. Frontiers in Nutrition, 2022, 9, 849034.	1.6	1
514	Comparative Efficacy of Single Pill Combinations of Azilsartan Medoxomil/Chlorthalidone and Losartan/Hydrochlorothiazide in Patients with Hypertension and Heart Failure with Preserved Ejection Fraction. Rational Pharmacotherapy in Cardiology, 2022, 18, 127-134.	0.3	0
515	20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units. Journal of Cardiovascular Development and Disease, 2022, 9, 149.	0.8	7

#	Article	IF	Citations
516	Management strategies in heart failure with preserved ejection fraction. Herz, 2022, 47, 332-339.	0.4	2
517	Integrin Î±11Î²1 and syndecan-4 dual receptor ablation attenuate cardiac hypertrophy in the pressure overloaded heart. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 322, H1057-H1071.	1.5	4
518	Relationship between adipose tissue distribution and arterial stiffness in HFpEF. Nutrition, 2022, 102, 111726.	1.1	5
519	A Bibliometric Analysis of Heart Failure with Preserved Ejection Fraction From 2000 to 2021. Current Problems in Cardiology, 2022, 47, 101243.	1.1	10
520	Aberrant static and dynamic functional network connectivity in heart failure with preserved ejection fraction. ESC Heart Failure, 2022, , .	1.4	1
521	Clinical Support through Telemedicine in Heart Failure Outpatients during the COVID-19 Pandemic Period: Results of a 12-Months Follow Up. Journal of Clinical Medicine, 2022, 11, 2790.	1.0	11
522	The cardiosplenic axis: the prognostic role of the spleen in heart failure. Heart Failure Reviews, 2022, 27, 2005-2015.	1.7	7
523	Clinical Phenotypes of HeartÂFailure With Preserved Ejection Fraction to Select Preclinical Animal Models. JACC Basic To Translational Science, 2022, 7, 844-857.	1.9	11
524	Mitochondrial DNA Is a Vital Driving Force in Ischemia-Reperfusion Injury in Cardiovascular Diseases. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-19.	1.9	6
525	Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. CKJ: Clinical Kidney Journal, 2022, 15, 2186-2199.	1.4	9
526	Prognostic Value of the MAGGIC Score, H2FPEF Score, and HFA-PEFF Algorithm in Patients with Exertional Dyspnea and the Incremental Value of Exercise Echocardiography. Journal of the American Society of Echocardiography, 2022, 35, 966-975.	1.2	7
527	Albumin-to-globulin ratio predicts clinical outcomes of heart failure with preserved ejection fraction in women. Heart and Vessels, 0, , .	0.5	1
528	Understanding the Role of SERCA2a Microdomain Remodeling in Heart Failure Induced by Obesity and Type 2 Diabetes. Journal of Cardiovascular Development and Disease, 2022, 9, 163.	0.8	4
529	The Obesity Paradox in Chronic Heart Disease and Chronic Obstructive Pulmonary Disease. Cureus, 2022, , .	0.2	7
530	p53â€Dependent Mitochondrial Compensation in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2022, 11, .	1.6	9
531	Remodeling of cardiac metabolism in heart failure with preserved ejection fraction. Current Opinion in Physiology, 2022, 27, 100559.	0.9	2
532	Phosphodiesterase inhibitor for heart failure with preserved ejection fraction: A systematic review and meta-analysis. Saudi Pharmaceutical Journal, 2022, 30, 1079-1087.	1.2	1
533	Inflammatory Macrophage Interleukin-1Î² Mediates High Fat Diet-Induced Heart Failure with Preserved Ejection Fraction. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
534	Devices that Enhance the Biomechanics of the Failing Heart. , 2022, , 625-640.		1
535	Heart failure with preserved ejection fraction update: A review of clinical trials and new therapeutic considerations. Cardiology Journal, 0, , .	0.5	3
536	In vivo imaging of heart failure with preserved ejection fraction by simultaneous monitoring of cardiac nitric oxide and glutathione using a three-channel fluorescent probe. Biosensors and Bioelectronics, 2022, 214, 114510.	5.3	7
537	Comorbidities in heart failure with preserved ejection fraction. Herz, 2022, 47, 301-307.	0.4	10
538	Heart Failure With Preserved Ejection Fraction: Heterogeneous Syndrome, Diverse Preclinical Models. Circulation Research, 2022, 130, 1906-1925.	2.0	45
539	Sex differences in vascular aging and impact of GPER deletion. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 323, H336-H349.	1.5	17
540	Intermittent Fasting as Possible Treatment for Heart Failure. Current Vascular Pharmacology, 2022, 20, 260-271.	0.8	5
541	Sex-specific phenotypes in the aging mouse heart and consequences for chronic fibrosis. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 323, H285-H300.	1.5	13
542	Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach. Current Heart Failure Reports, 2022, 19, 290-302.	1.3	11
543	Nâ€ofâ€1 trials to facilitate evidenceâ€based deprescribing: Rationale and case study. British Journal of Clinical Pharmacology, 2022, 88, 4460-4473.	1.1	8
544	Pressure Overload Activates DNA-Damage Response in Cardiac Stromal Cells: A Novel Mechanism Behind Heart Failure With Preserved Ejection Fraction?. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
545	Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction. Cardiovascular Research, 2023, 118, 3586-3601.	1.8	9
546	Histamine H2 receptor antagonist exposure was related to decreased all-cause mortality in critical ill patients with heart failure: a cohort study. European Journal of Preventive Cardiology, 2022, 29, 1854-1865.	0.8	9
547	What is actually preserved in HFpEF? Focus on myocyte calcium handling remodelling. Journal of Molecular and Cellular Cardiology, 2022, 170, 115-116.	0.9	0
548	Current Updates in the Pharmacotherapy of Heart Failure with a Preserved Ejection Fraction. Cardiovascular & Hematological Disorders Drug Targets, 2022, 22, 87-95.	0.2	1
549	What have we learned so far from the sex/gender issue in heart failure? An overview of current evidence. Internal and Emergency Medicine, 0, , .	1.0	2
550	Clinical Evidence and Proposed Mechanisms of Sodiumâ€“Glucose CotransporterÂ2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?. Cardiac Failure Review, 0, 8, .	1.2	9
551	Reshaping Treatment of Heart Failure with Preserved Ejection Fraction. Journal of Clinical Medicine, 2022, 11, 3706.	1.0	2

#	Article	IF	Citations
552	Novel Phenotyping for Acute Heart Failureâ€"Unsupervised Machine Learning-Based Approach. Biomedicines, 2022, 10, 1514.	1.4	8
553	Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction. Frontiers in Physiology, 0, 13, .	1.3	13
554	Right ventricular performance in patients with heart failure with mildly reduced ejection fraction: the forgotten ventricle. International Journal of Cardiovascular Imaging, 2022, 38, 2363-2372.	0.2	3
555	Left Ventricular Diastolic Dysfunction and Progression of Chronic Kidney Disease: Analysis of KNOWâ€CKD Data. Journal of the American Heart Association, 2022, 11, .	1.6	7
556	What dietary interventions have been tested in heart failure with preserved ejection fraction? A systematic scoping review. European Journal of Cardiovascular Nursing, 2023, 22, 126-140.	0.4	3
557	Dirty Jobs: Macrophages at the Heart of Cardiovascular Disease. Biomedicines, 2022, 10, 1579.	1.4	4
558	Sex differences in heart mitochondria regulate diastolic dysfunction. Nature Communications, 2022, 13, .	5.8	30
559	A Data Mining-Based Study on Medication Rules of Chinese Herbs to Treat Heart Failure with Preserved Ejection Fraction. Chinese Journal of Integrative Medicine, 2022, 28, 847-854.	0.7	8
560	Colchicine alleviates inflammation and improves diastolic dysfunction in heart failure rats with preserved ejection fraction. European Journal of Pharmacology, 2022, 929, 175126.	1.7	16
561	Clinical Phenotypes of Heart Failure across the spectrum of Ejection Fraction: A Cluster Analysis. Current Problems in Cardiology, 2022, 47, 101337.	1.1	2
562	Value of the <scp>HFAâ€PEFF</scp> and <scp>H₂FPEF</scp> scores inÂpatients with heart failure and preserved ejection fraction caused by cardiac amyloidosis. European Journal of Heart Failure, 2022, 24, 2374-2386.	2.9	24
563	Ectopic fat is associated with cardiac remodelingâ€"A comprehensive assessment of regional fat depots in type 2 diabetes using multi-parametric MRI. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	5
564	Multispecialty multidisciplinary input into comorbidities along with treatment optimisation in heart failure reduces hospitalisation and clinic attendance. Open Heart, 2022, 9, e001979.	0.9	7
565	Prevalence of Thyroid Dysfunction Among Patients with Heart Failure at a Tertiary Hospital in Mogadishu, Somalia. International Journal of General Medicine, 0, Volume 15, 6335-6339.	0.8	7
566	Incidence of Preclinical Heart Failure in a Community Population. Journal of the American Heart Association, 0, , .	1.6	3
567	Catheter Ablation Versus Medical Therapy for Atrial Fibrillation in Patients with Heart failure: A Meta-Analysis of Randomized Controlled Trials. , 0, , .		0
568	Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with heart failure and preserved, mildly reduced, and reduced ejection fraction: A systemic review and meta-analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
569	Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovascular Research, 2023, 118, 3434-3450.	1.8	49

#	Article	IF	Citations
570	Effects of Exercise on Heart Failure with Preserved Ejection Fraction: An Updated Review of Literature. Journal of Cardiovascular Development and Disease, 2022, 9, 241.	0.8	15
571	Systems Pharmacology-Based Strategy to Investigate Pharmacological Mechanisms of Total Flavonoids in Dracocephalum moldavica on Chronic Heart Failure. International Journal of Molecular Sciences, 2022, 23, 8409.	1.8	4
572	Genomic, Proteomic, and Metabolic Comparisons of Small Animal Models of Heart Failure With Preserved Ejection Fraction: A Tale of Mice, Rats, and Cats. Journal of the American Heart Association, 2022, 11, .	1.6	6
573	Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction. Cardiac Failure Review, 0, 8, .	1.2	19
574	Arrhythmic Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction: Mechanisms, Genetics, and Future Directions. CJC Open, 2022, 4, 959-969.	0.7	3
575	Age and sex hormones modulate left ventricle regional response to angiotensin II in male and female mice. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 323, H643-H658.	1.5	2
576	Clinical characteristics and 1â€year outcomes in hospitalized patients with heart failure with preserved ejection fraction: results from the China Cardiovascular Association <scp>Databaseâ€Heart</scp> Failure Center Registry. European Journal of Heart Failure, 2022, 24, 2048-2062.	2.9	20
577	Hospitalization following an emergency-department visit for worsening heart failure: The role of left ventricular ejection fraction. Medicina ClÃnica (English Edition), 2022, 159, 157-163.	0.1	0
578	Targeting pulmonary hypertension in patients with heart failure and preserved ejection fraction: rather static than DYNAMIC development?. European Heart Journal, 2022, 43, 3414-3416.	1.0	5
579	Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?. International Journal of Molecular Sciences, 2022, 23, 8631.	1.8	7
580	SAR296968, a Novel Selective Na+/Ca2+ Exchanger Inhibitor, Improves Ca2+ Handling and Contractile Function in Human Atrial Cardiomyocytes. Biomedicines, 2022, 10, 1932.	1.4	7
581	Machine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: Findings from ASCEND-HF. American Heart Journal, 2022, 254, 112-121.	1.2	6
582	Biomarkers and the quadriceps femoris muscle architecture assessed by ultrasound in older adults with heart failure with preserved ejection fraction: a cross-sectional study. Aging Clinical and Experimental Research, 2022, 34, 2493-2504.	1.4	6
583	Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial. European Heart Journal, 2022, 43, 3402-3413.	1.0	31
584	Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	6
585	Cell therapy attenuates endothelial dysfunction in hypertensive rats with heart failure and preserved ejection fraction. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 323, H892-H903.	1.5	8
586	DELIVERing Progress in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2022, 387, 1138-1140.	13.9	8
587	Evaluating heart failure predictors using quantitative approaches. AIP Conference Proceedings, 2022, , .	0.3	0

#	Article	IF	Citations
588	Bibliometric Analysis of Traditional Chinese Medicine Research on Heart Failure in the 21st Century Based on the WOS Database. SSRN Electronic Journal, 0, , .	0.4	1
589	Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. Circulation: Heart Failure, 2022, 15, .	1.6	32
590	Disturbed Cardiac Metabolism Triggers Atrial Arrhythmogenesis in Diabetes Mellitus: Energy Substrate Alternate as a Potential Therapeutic Intervention. Cells, 2022, 11, 2915.	1.8	1
591	Incidence and Causal Association of Functional Atrial Mitral Regurgitation in HFpEF. Hellenic Journal of Cardiology, 2022, , .	0.4	1
592	Sex differences in ventricular arrhythmias epidemiology, risk factors, and mortality in congestive heart failure. International Journal of Cardiology, 2022, , .	0.8	1
593	Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure. Science, 2022, 377, 1399-1406.	6.0	44
595	Inorganic phosphate accelerates cardiac myofilament relaxation in response to lengthening. Frontiers in Physiology, 0, 13, .	1.3	1
596	Cumulative complexity: a qualitative analysis of patientsâ€™ experiences of living with heart failure with preserved ejection fraction. European Journal of Cardiovascular Nursing, 2023, 22, 529-536.	0.4	1
597	NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction. Antioxidants, 2022, 11, 1822.	2.2	14
598	Role of copeptin in diagnosis and outcome prediction in patients with heart failure: a systematic review and meta-analysis. Biomarkers, 2022, 27, 720-726.	0.9	1
599	Potential Benefits of Sodium-Glucose Transporter-2 Inhibitors in the Symptomatic and Functional Status of Patients With Heart Failure: A Systematic Review and Meta-Analysis. Cureus, 2022, , .	0.2	1
600	SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	6
601	Molecular imaging of fibroblast activity in pressure overload heart failure using [68ÂGa]Ga-FAPI-04 PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 465-474.	3.3	12
602	Does global longitudinal strain improve stratification risk in heart failure with preserved ejection fraction?. Journal of Cardiology and Cardiovascular Medicine, 2022, 7, 074-080.	0.1	0
603	Exercise training ameliorates myocardial phenotypes in heart failure with preserved ejection fraction by changing N6-methyladenosine modification in mice model. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	5
604	Evaluation of strain echocardiography and atrial electromechanical delay in patients with idiopathic carpal tunnel syndrome. Journal of Health Sciences and Medicine, 2022, 5, 1385-1389.	0.0	0
606	Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIASTâ€CHF study. ESC Heart Failure, 2023, 10, 200-210.	1.4	7
607	Features of Prediction of Heart Failure in Patients with Peripheral Atherosclerosis During a Three-Year Prospective Follow-Up. Russian Archives of Internal Medicine, 2022, 12, 380-388.	0.0	0

#	Article	IF	Citations
608	SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2022, 18, 579-586.	1.0	3
609	Acetylation and phosphorylation changes to cardiac proteins in experimental HFpEF due to metabolic risk reveal targets for treatment. Life Sciences, 2022, 309, 120998.	2.0	4
610	Key Phenotypes of Heart Failure with Preserved Ejection Fraction. Cardiology Clinics, 2022, 40, 415-429.	0.9	1
611	The Role of Multimodality Imaging in the Evaluation of Heart Failure with Preserved Ejection Fraction. Cardiology Clinics, 2022, 40, 443-457.	0.9	2
612	Mitochondrial oxidative stress contributes to diastolic dysfunction through impaired mitochondrial dynamics. Redox Biology, 2022, 57, 102474.	3.9	13
613	HFpEF etiology â€“ Can focus on sex-specific mechanisms deliver insights for all?. Journal of Molecular and Cellular Cardiology, 2022, 173, 71-72.	0.9	2
614	SIRT6 Mitigates Heart Failure With Preserved Ejection Fraction in Diabetes. Circulation Research, 2022, 131, 926-943.	2.0	18
615	Sex, lean body mass, and cardiac performance. Science Translational Medicine, 2022, 14, .	5.8	4
616	Increased Soluble Epoxide Hydrolase Activity Positively Correlates with Mortality in Heart Failure Patients with Preserved Ejection Fraction: Evidence from Metabolomics. Phenomics, 2023, 3, 34-49.	0.9	2
617	Angiopoietins, vascular endothelial growth factors and secretory phospholipase A2 in heart failure patients with preserved ejection fraction. European Journal of Internal Medicine, 2022, 106, 111-119.	1.0	6
618	Material property alterations for phenotypes of heart failure with preserved ejection fraction: A numerical study of subject-specific porcine models. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	1
620	Cardiac and Cancer-Associated Cachexia: Role of Exercise Training, Non-coding RNAs, and Future Perspectives. , 0, , .		1
621	Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China. Frontiers in Pharmacology, 0, 13, .	1.6	9
622	Gender Differences in Anxiety, Depression, Insomnia, and Quality of Life in Heart Failure With Preserved Ejection Fraction: A Multicenter, Cross-sectional Study. Journal of Cardiovascular Nursing, 0, Publish Ahead of Print, .	0.6	0
623	Effects of L-Citrulline Supplementation on Endothelial Function and Blood Pressure in Hypertensive Postmenopausal Women. Nutrients, 2022, 14, 4396.	1.7	10
624	Machine Learning Approach to Understand Worsening Renal Function in Acute Heart Failure. Biomolecules, 2022, 12, 1616.	1.8	2
625	Distinct implications of body mass index in different subgroups of nonobese patients with heart failure with preserved ejection fraction: a latent class analysis of data from the TOPCAT trial. BMC Medicine, 2022, 20, .	2.3	4
626	Relationship of Circulating Vegetable Omega-3 to Prognosis in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2022, 80, 1751-1758.	1.2	8

#	Article	IF	Citations
627	INFLUENCE OF POSTMENOPAUSE ON THE FORMATION OF CHRONIC HEART FAILURE IN WOMEN WITH ARTERIAL HYPERTENSION. Bulletin of Problems Biology and Medicine, 2022, 1, 45.	0.0	1
628	N6-methyladenosine (m6A) RNA modification in the pathophysiology of heart failure: a narrative review. Cardiovascular Diagnosis and Therapy, 2022, 12, 908-925.	0.7	2
629	Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. Circulation, 2023, 147, 624-634.	1.6	18
630	Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials. Cardiovascular Diabetology, 2022, 21, .	2.7	3
631	Does exercise training improve exercise tolerance, quality of life, and echocardiographic parameters in patients with heart failure with preserved ejection fraction? A systematic review and meta-analysis of randomized controlled trials. Heart Failure Reviews, 2023, 28, 795-806.	1.7	2
632	Effect of Sacubitril-Valsartan on Quality of Life, Functional and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (HFpEF): A Systematic Review of Randomized Clinical Trials. Hearts, 2022, 3, 129-136.	0.4	0
633	A potential role of autophagy-mediated vascular senescence in the pathophysiology of HFpEF. Frontiers in Endocrinology, 0, 13, .	1.5	4
634	A Rare Case of Phentermine-Induced Nonischemic Cardiomyopathy. Cureus, 2022, , .	0.2	0
635	Towards a More Individually Tailored Exercise Prescription for Promoting Cardiovascular Health. Journal of Cardiovascular Development and Disease, 2022, 9, 401.	0.8	0
636	The predictive value of changes in left atrial volume index for rehospitalization in heart failure with preserved ejection fraction. Clinical Cardiology, 2023, 46, 151-158.	0.7	2
637	A retrospective study on the clinical significance of cardiac computed tomography in heart failure patients with preserved ejection fraction. Annals of Translational Medicine, 2022, .	0.7	0
638	Heart failure with preserved left ventricular ejection fraction: a comprehensive phenotype-based approach to diagnosis and treatment. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2022, 15, 627.	0.1	0
639	Adiposity and clinical outcomes in East Asian patients with heart failure and preserved ejection fraction. IJC Heart and Vasculature, 2023, 44, 101162.	0.6	0
640	The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies. , 2023, 14, 46.		9
641	MARKER DIAGNOSTIC HEART FAILURE PROGRESSION IN THE POST-INFARCTION PERIOD. WiadomoÅ›ci Lekarskie, 2022, 75, 2476-2480.	0.1	1
642	Inflammatory Macrophage Interleukin-1Î² Mediates High-Fat Diet-Induced HeartÂFailure With Preserved EjectionÂFraction. JACC Basic To Translational Science, 2023, 8, 174-185.	1.9	10
643	Systemic Delivery of Extracellular Vesicles Attenuates Atrial Fibrillation inÂHeartÂFailure With Preserved EjectionÂFraction. JACC: Clinical Electrophysiology, 2023, 9, 147-158.	1.3	6
644	Safety and efficacy of acupuncture for anxiety and depression in patients with heart failure: A protocol for systematic review and meta-analysis. Medicine (United States), 2022, 101, e31822.	0.4	1

#	Article	IF	Citations
645	Comparative Analysis of Non-Coding RNA Transcriptomics in Heart Failure. Biomedicines, 2022, 10, 3076.	1.4	5
646	Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. European Heart Journal, 2023, 44, 411-421.	1.0	89
647	Association between phonocardiography and echocardiography in heart failure patients with preserved ejection fraction. European Heart Journal Digital Health, 0, , .	0.7	1
648	Evidence for empagliflozin in heart failure with preserved ejection fraction (HFpEF). Drug and Therapeutics Bulletin, 2023, 61, 22-23.	0.3	1
649	Cardiac metabolism in HFpEF: from fuel to signalling. Cardiovascular Research, 2023, 118, 3556-3575.	1.8	20
650	Incidence of atrial functional tricuspid regurgitation and its correlation with tricuspid valvular deformation in patients with persistent atrial fibrillation. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
651	IGFBP7 on the road to heart failure: driver or passenger?. , 2022, 1, 1121-1123.		0
652	Heart failure with preserved left ventricular ejection fraction amidst diabetes mellitus: from general mechanisms to possible therapy tactics. Cardiosomatics, 2022, 13, 115-123.	0.2	0
653	Diagnostic signature for heart failure with preserved ejection fraction (HFpEF): a machine learning approach using multi-modality electronic health record data. BMC Cardiovascular Disorders, 2022, 22, .	0.7	2
654	Heart Failure in Menopause: Treatment and New Approaches. International Journal of Molecular Sciences, 2022, 23, 15140.	1.8	3
655	The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?. European Heart Journal Supplements, 2022, 24, L10-L19.	0.0	6
657	Twenty-year changes in the clinical and echocardiographic characteristics of patients with early postinfarction remodeling after primary ST-segment elevation myocardial infarction. Russian Journal of Cardiology, 2023, 27, 4951.	0.4	0
658	Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on HeartÂFailureÂWith Preserved EjectionÂFraction and Diabetes. JACC Asia, 2023, 3, 93-104.	0.5	8
659	Prevalence and prognosis of frailty in older patients with stage B heart failure with preserved ejection fraction. ESC Heart Failure, 2023, 10, 1133-1143.	1.4	4
660	Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans. Drug Metabolism and Disposition, 2023, 51, 451-463.	1.7	2
661	Bibliometric analysis of traditional Chinese medicine research on heart failure in the 21st century based on the WOS database. Heliyon, 2023, 9, e12770.	1.4	2
662	Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
663	Association between the risk of heart failure hospitalization and end-stage renal disease with digoxin usage in patients with cardiorenal syndrome: A population-based study. Frontiers in Public Health, 0, 10, .	1.3	0

#	Article	IF	Citations
664	Genetically determined serum bilirubin level and the risk of heart failure: A mendelian randomization study. Frontiers in Genetics, 0, 14, .	1.1	1
665	Extent of coronary atherosclerosis is associated with deterioration of left ventricular global longitudinal strain in patients with preserved ejection fraction undergoing coronary computed tomography angiography. IJC Heart and Vasculature, 2023, 44, 101176.	0.6	1
666	Diet modification reverses diastolic dysfunction in rats with heart failure and preserved ejection fraction. , 2023, 3, 100031.		1
667	Diastolic dysfunction and sex-specific progression to HFpEF: current gaps in knowledge and future directions. BMC Medicine, 2022, 20, .	2.3	10
668	Potential new application points of SGLT2 inhibitors in patients with heart failure in combination with diabetes mellitus, non-alcoholic fatty liver disease and anemia (literature review). The Siberian Scientific Medical Journal, 2022, 42, 4-14.	0.1	1
669	New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedsideâ€¦ and Back. Biomedicines, 2023, 11, 70.	1.4	1
670	Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	11
671	Association between visceral adiposity index and heart failure: A crossâ€sectional study. Clinical Cardiology, 2023, 46, 310-319.	0.7	6
672	Global trends in research on oxidative stress related to heart failure from 2012 to 2021: a bibliometric analysis and suggestion to researchers. Annals of Translational Medicine, 2023, 11, 54-54.	0.7	1
673	Addressing persistent evidence gaps in cardiovascular sex differences research â€“ the potential of clinical care data. Frontiers in Global Women S Health, 0, 3, .	1.1	0
674	Disparities in prevalence of heart failure between the genders in relation to age, multimorbidity and socioeconomic status in southern Sweden: a cross-sectional study. Scandinavian Journal of Primary Health Care, 2023, 41, 160-169.	0.6	0
675	Clinical profiling of end-stage heart failure with preserved ejection fraction: The National Readmission Database. International Journal of Cardiology, 2023, 378, 71-76.	0.8	0
677	Prediction Model Based on Easily Available Markers for Aberrant Cardiac Remodeling in Women After Pregnancy. Hypertension, 0, , .	1.3	0
678	Biomarker-Based Guideline-Directed Medical Therapy of Heart Failure: The Gap Between Guidelines and Clinical Practice. EMJ Cardiology, 0, , 67-76.	0.0	0
679	The Interaction of Gut Microbiota and Heart Failure with Preserved Ejection Fraction: From Mechanism to Potential Therapies. Biomedicines, 2023, 11, 442.	1.4	6
680	Association of serum N-terminal pro-brain natriuretic peptide levels with survival and renal outcomes among elderly patients with acute kidney injury in chronic heart failure. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	1
681	The controversial role of beta-blockers in heart failure with preserved ejection fraction. , 2023, 243, 108356.		4
682	Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	2

#	Article	IF	Citations
683	Too Little of a Good Thing. JACC: Cardiovascular Imaging, 2023, 16, 768-778.	2.3	9
684	Serum Uric Acid Predicts All-Cause and Cardiovascular Mortality Independently of Hypertriglyceridemia in Cardiometabolic Patients without Established CV Disease: A Sub-Analysis of the URic acid Right for heArt Health (URRAH) Study. Metabolites, 2023, 13, 244.	1.3	6
685	Combination Sodium Nitrite and Hydralazine Therapy Attenuates Heart Failure With Preserved Ejection Fraction Severity in a â€œ2â€Hitâ€•Murine Model. Journal of the American Heart Association, 2023, 12, .	1.6	10
686	Calcium â€œstressâ€•adds a third hit in driving heart failure with preserved ejection fraction. American Journal of Physiology - Heart and Circulatory Physiology, 2023, 324, H414-H416.	1.5	0
687	The clinical burden of newly diagnosed Heart failure among patients with Reduced, mildly Reduced, and preserved ejection fraction. IJC Heart and Vasculature, 2023, 47, 101182.	0.6	1
689	Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction. Annals of Pharmacotherapy, 2023, 57, 1291-1301.	0.9	1
691	Epigenetic Signatures in Arterial Hypertension: Focus on the Microvasculature. International Journal of Molecular Sciences, 2023, 24, 4854.	1.8	0
692	Physician Perspectives on the Use of Beta Blockers in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2023, 193, 70-74.	0.7	3
693	Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2023, 8, 419.	3.0	21
694	Serum uric acid: A risk factor for right ventricular dysfunction and prognosis in heart failure with preserved ejection fraction. Frontiers in Endocrinology, 0, 14, .	1.5	4
695	Serum Proâ€Nâ€Cadherin Is a Marker of Subclinical Heart Failure in the General Population. Journal of the American Heart Association, 2023, 12, .	1.6	4
696	Long-term prognosis of patients with chronic heart failure and reduced left ventricular ejection fraction receiving cardiac contractility modulation therapy: the impact of comorbidity burden on outcomes. Journal of Arrhythmology, 2023, 30, 42-51.	0.1	0
697	All-Cause and Cardiovascular-Related Mortality in CKD Patients With and Without Heart Failure: A Population-Based Cohort Study in Kaiser Permanente Southern California. Kidney Medicine, 2023, 5, 100624.	1.0	2
698	Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2023, 329, 827.	3.8	82
700	Trends in Incidence of Chronic Heart Failure in Patients With Rheumatoid Arthritis: A Population-Based Study Validating Different Heart Failure Definitions. Journal of Rheumatology, 2023, 50, 881-888.	1.0	1
701	Diagnostic value of expired gas analysis in heart failure with preserved ejection fraction. Scientific Reports, 2023, 13, .	1.6	2
702	Un facteur causal deÂlâ€™insuffisance cardiaque. Medecine/Sciences, 2023, 39, 293-295.	0.0	0
703	Afterload increase challenge unmasks systolic abnormalities in heart failure with preserved ejection fraction. International Journal of Cardiology, 2023, 380, 20-27.	0.8	2

#	Article	IF	Citations
704	Management of patients with heart failure and preserved ejection fraction. Heart, 2023, 109, 874-883.	1.2	9
705	Evaluation of large animal models for preclinical studies of heart failure with preserved ejection fraction using clinical score systems. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	0
706	Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers. Clinical Drug Investigation, 2023, 43, 241-250.	1.1	0
707	Association between the NEP rs701109 polymorphism and the clinical efficacy and safety of sacubitril/valsartan in Chinese patients with heart failure. European Journal of Clinical Pharmacology, 2023, 79, 663-670.	0.8	2
708	Heart Failure with Preserved Ejection Fraction. , 2023, , 89-106.		0
709	Do we need dedicated heart failure with preserved ejection fraction clinics?. European Heart Journal, 2023, 44, 1557-1559.	1.0	3
710	Inflammatory Mechanisms in Heart Failure with Preserved Ejection Fraction. Physiology, 0, , .	1.6	1
711	Blinded, randomized trial of sonographer versus AI cardiac function assessment. Nature, 2023, 616, 520-524.	13.7	46
712	Cardiac rehabilitation utilization, barriers, and outcomes among patients with heart failure. Heart Failure Reviews, 2023, 28, 1239-1249.	1.7	5
713	Visualization of Activated Fibroblasts in Heart Failure with Preserved Ejection Fraction with [¹⁸F]AlF-NOTA-FAPI-04 PET/CT Imaging. Molecular Pharmaceutics, 2023, 20, 2634-2641.	2.3	6
714	Metabolic Acidosis Results in Sexually Dimorphic Response in the Heart Tissue. Metabolites, 2023, 13, 549.	1.3	2
715	Diastolic Function and Fibrosis Burden. JACC: Cardiovascular Imaging, 2023, 16, 797-799.	2.3	1
716	Sodium-glucose cotransporter type 2 inhibitors in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. Cardiosomatics, 2023, 13, 198-205.	0.2	0
717	Contemporary insights into the epidemiology, impact and treatment of secondary tricuspid regurgitation across the heart failure spectrum. European Journal of Heart Failure, 2023, 25, 857-867.	2.9	7
718	FFAR4 regulates cardiac oxylipin balance to promote inflammation resolution in HFpEF secondary to metabolic syndrome. Journal of Lipid Research, 2023, 64, 100374.	2.0	3
719	Hypertensive response to exercise, hypertension and heart failure with preserved ejection fraction (HFpEF)â€"aÂcontinuum of disease?. Wiener Klinische Wochenschrift, 0, , .	1.0	0
720	Cardiac Microvascular Endothelial Cells and Pressure Overload-Induced Cardiac Fibrosis. Cardiac and Vascular Biology, 2023, , 229-264.	0.2	0
721	HeartÂFailure With Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2023, 81, 1810-1834.	1.2	61

#	Article	IF	Citations
722	Atrial Fibrillation can adversely impact Heart Failure with Preserved Ejection Fraction by its association with Heart Failure Progression and Mortality: A Post-Hoc Propensity Scoreâ€“Matched Analysis of the TOPCAT Americas Trial. Europace, 2023, 25, .	0.7	2
723	Coronary Artery Spasm-Related Heart Failure Syndrome: Literature Review. International Journal of Molecular Sciences, 2023, 24, 7530.	1.8	2
724	Soluble Guanylate Cyclase Activators and Stimulators in Patients with Heart Failure. Current Cardiology Reports, 2023, 25, 607-613.	1.3	2
727	Hallmarks of cardiovascular ageing. Nature Reviews Cardiology, 2023, 20, 754-777.	6.1	28
760	Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges. Nature Reviews Cardiology, 2023, 20, 812-829.	6.1	14
774	Diagnosis and Management of Heart FailureÂin Children. , 2023, , 1-39.		0
785	Myocardial Metabolic Reprogramming in HFpEF. Journal of Cardiovascular Translational Research, 2024, 17, 121-132.	1.1	1
793	Recent successes in heart failure treatment. Nature Medicine, 2023, 29, 2424-2437.	15.2	4
815	The glycolytic pathway to heart failure. , 2024, , 235-266.		0
836	Sex-Dependent Differences in the Diagnosis, Treatment and Causes of Heart Failure. , 2023, , 245-262.		0
837	Sex-Dependent Cardiac Fibrosis After Myocardial Infarction: A Function of Differential Periostin Signaling?. , 2023, , 263-277.		0
846	Management of Cardiovascular Disease in the Elderly. , 2023, , 1-41.		0
849	Exploring the Mechanistic Link Between Obesity and Heart Failure. Current Diabetes Reports, 0, , .	1.7	0
858	STEP-HFpEF: Semaglutide safe and efficacious in HFpEF plus obesity. , 0, , .		0
876	Decrypting the role of angiogenesis, inflammation, and oxidative stress in pathogenesis of congestive heart failure: Nanotechnology as a boon for the management of congestive heart failure. , 2024, , 151-190.		0
886	Management of Cardiovascular Disease in the Elderly. , 2024, , 343-383.		0